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A B S T R A C T
Background
Guidelines suggest limited and cautious use of antipsychotics for treatment of delirium where nonpharmacological interventions have
failed and symptoms remain distressing or dangerous, or both. It is unclear how well these recommendations are supported by current
evidence.
Objectives
Our primary objective was to assess the efficacy of antipsychotics versus nonantipsychotics or placebo on the duration of delirium in
hospitalised adults. Our secondary objectives were to compare the efficacy of: 1) antipsychotics versus nonantipsychotics or placebo
on delirium severity and resolution, mortality, hospital length of stay, discharge disposition, health-related quality of life, and adverse
effects; and 2) atypical vs. typical antipsychotics for reducing delirium duration, severity, and resolution, hospital mortality and length
of stay, discharge disposition, health-related quality of life, and adverse effects.
Search methods
We searchedMEDLINE, Embase, Cochrane EBM Reviews, CINAHL, Thomson Reuters Web of Science and the Latin American and
Caribbean Health Sciences Literature (LILACS) from their respective inception dates until July 2017. We also searched the Database
of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database, Web of Science ISI Proceedings, and other grey
literature.
Selection criteria
We included randomised and quasi-randomised trials comparing 1) antipsychotics to nonantipsychotics or placebo and 2) typical to
atypical antipsychotics for the treatment of delirium in adult hospitalised (but not critically ill) patients.
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Data collection and analysis
We examined titles and abstracts of identified studies to determine eligibility. We extracted data independently in duplicate. Disagree-
ments were settled by further discussion and consensus. We used risk ratios (RR) with 95% confidence intervals (CI) as a measure of
treatment effect for dichotomous outcomes, and between-group standardised mean differences (SMD) with 95% CI for continuous
outcomes.
Main results
We included nine trials that recruited 727 participants. Four of the nine trials included a comparison of an antipsychotic to a
nonantipsychotic drug or placebo and seven included a comparison of a typical to an atypical antipsychotic. The study populations
included hospitalised medical, surgical, and palliative patients.
No trial reported on duration of delirium. Antipsychotic treatment did not reduce delirium severity compared to nonantipsychotic
drugs (standard mean difference (SMD) -1.08, 95% CI -2.55 to 0.39; four studies; 494 participants; very low-quality evidence); nor
was there a difference between typical and atypical antipsychotics (SMD -0.17, 95% CI -0.37 to 0.02; seven studies; 542 participants;
low-quality evidence). There was no evidence antipsychotics resolved delirium symptoms compared to nonantipsychotic drug regimens
(RR 0.95, 95% CI 0.30 to 2.98; three studies; 247 participants; very low-quality evidence); nor was there a difference between typical
and atypical antipsychotics (RR 1.10, 95% CI 0.79 to 1.52; five studies; 349 participants; low-quality evidence). The pooled results
indicated that antipsychotics did not alter mortality compared to nonantipsychotic regimens (RR 1.29, 95% CI 0.73 to 2.27; three
studies; 319 participants; low-quality evidence) nor was there a difference between typical and atypical antipsychotics (RR 1.71, 95%
CI 0.82 to 3.35; four studies; 342 participants; low-quality evidence).
No trial reported on hospital length of stay, hospital discharge disposition, or health-related quality of life. Adverse event reporting
was limited and measured with inconsistent methods; in those reporting events, the number of events were low. No trial reported on
physical restraint use, long-term cognitive outcomes, cerebrovascular events, or QTc prolongation (i.e. increased time in the heart’s
electrical cycle). Only one trial reported on arrhythmias and seizures, with no difference between typical or atypical antipsychotics. We
found antipsychotics did not have a higher risk of extrapyramidal symptoms (EPS) compared to nonantipsychotic drugs (RR 1.70,
95% CI 0.04 to 65.57; three studies; 247 participants; very-low quality evidence); pooled results showed no increased risk of EPS with
typical antipsychotics compared to atypical antipsychotics (RR 12.16, 95% CI 0.55 to 269.52; two studies; 198 participants; very low-
quality evidence).
Authors’ conclusions
There were no reported data to determine whether antipsychotics altered the duration of delirium, length of hospital stay, discharge
disposition, or health-related quality of life as studies did not report on these outcomes. From the poor quality data available, we found
antipsychotics did not reduce delirium severity, resolve symptoms, or alter mortality. Adverse effects were poorly or rarely reported in
the trials. Extrapyramidal symptoms were not more frequent with antipsychotics compared to nonantipsychotic drug regimens, and
no different for typical compared to atypical antipsychotics.
P L A I N L A N G U A G E S U M M A R Y
Antipsychotics to treat delirium in hospitalised patients, not including those in intensive care units
Review question
We reviewed the evidence for the effectiveness and safety of antipsychotics for treatment of delirium in hospitalised patients, not
including those in intensive care units (specialised wards for caring for very sick patients).
Background
Delirium is a public health concern as it is a new onset confused state that increases the amount of time patients spend in the hospital,
as well as their chance of dying. Guidelines recommendations include reversal of any potential medical or drug triggers that may be
contributing to delirium. If delirium symptoms persist and are distressing or dangerous, an antipsychotic drug may be prescribed for
a short time. Antipsychotic drugs, also known as tranquillizers, are mainly used to treat psychosis (e.g. hallucinations). There are two
types of antipsychotics: first generation or typical antipsychotics (e.g. haloperidol) and second generation or atypical antipsychotics
(e.g. quetiapine). Both groups of antipsychotics block the brain’s dopamine receptor pathways but atypical antipsychotics also act on
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serotonin receptors. Atypical antipsychotics are also noted to be effective for treating both the positive symptoms (e.g. hallucinations)
as well as the negative symptoms (e.g. emotional withdrawal) of psychosis. We need to understand if antipsychotics shorten the course
of delirium or reduce symptoms or if they cause more harm. Therefore, we updated the existing Cochrane Review from 2007.
Study characteristics
We found nine studies with 727 participants testing antipsychotics for delirium treatment; four trials compared an antipsychotic to
another drug class or placebo and seven of the nine trials compared a typical antipsychotic to an atypical antipsychotic.
Key findings
We found no evidence to support or refute the suggestion that antipsychotics shorten the course of delirium in hospitalised patients.
Based on the available studies, antipsychotics do not reduce the severity of delirium or resolve symptoms compared to nonantipsychotic
drugs or placebo or lower the risk of dying. We found no evidence to support or refute the suggestion that antipsychotics shorten
hospital length of stay or improve health-related quality of life. Side effects were rarely reported in the studies.
Quality of the Evidence
It is important to note many clinically relevant outcomes were not reported in the studies and the overall quality of the available evidence
was poor.
External funding
Canadian Fraility Network (previously Technology Evaluation in the Elderly Network [TVN]) (www.cfn-nce.ca/), Canada
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antipsychotics for the treatment of delirium in hospitalised patients
Patient or population: delirious pat ients
Settings: hospital wards, not ICU
Intervention: ant ipsychot ics drugs
Comparison: nonant ipsychot ics drugs or placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Non-antipsychotics
drugs or Placebo
Antipsychotics drugs
Duration of delirium
Follow-up: days
This outcome was not
reported in any trial.
Delirium severity
DRS, DRS-R98, MDAS1
Follow-up: up to 10
days
The mean DRS-R-98
score was was 22.7 (3.
1) at baseline and 7.4
(SD 3.3) at the end of
study.16
The standardised delir-
ium severity score was
1.08 points lower in the
intervent ion group (2.
55 lower to 0.39 higher)
.
494
(4 studies)
⊕©©©
Very low-quality: we
have very lit t le conf i-
dence in the ef fect es-
t imate; the true ef fect
is likely to be sub-
stant ially dif f erent f rom
the est imate of ef fect.
2,3,4,5
SMD -1.08 (-2.55 to 0.
39)
Delirium resolution
DRS, DRS-R981
Follow-up: up to 10
days
Study population RR 0.95
(0.3 to 2.98)
247
(3 studies)
⊕©©©
Very low-quality: we
have very lit t le conf i-
dence in the ef fect es-
t imate; the true ef fect
is likely to be sub-
stant ially dif f erent f rom
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the est imate of ef fect.
6,7,8,9,10
268 per 1000 254 per 1000
(80 to 798)
Moderate
191 per 1000 181 per 1000
(57 to 569)
Mortality
Follow-up: up to 10
days
Study population RR 1.29
(0.73 to 2.27)
319
(3 studies)
⊕⊕©©
Low-quality: we are
moderately conf ident in
the ef fect est imate; the
true ef fect is likely to
be close to the est imate
of ef fect, but there is a
possibility that it is sub-
stant ially dif f erent.11,12
126 per 1000 163 per 1000
(92 to 286)
Moderate
143 per 1000 184 per 1000
(104 to 325)
Hospital length of stay
Follow-up: days
This outcome was not
reported in any trial.
Adverse Effects - EPS
Extrapyramidal Symp-
tom Rating Scale, or not
reported
Follow-up: up to 10
days
Study population RR 1.7
(0.04 to 65.57)
247
(3 studies)
⊕©©©
Very low-quality: we
have very lit t le conf i-
dence in the ef fect es-
t imate; the true ef fect
is likely to be sub-
stant ially dif f erent f rom
the est imate of ef fect.
13,14,15
54 per 1000 91 per 1000
(2 to 1000)
Moderate
0 per 1000 0 per 1000
(0 to 0)
5
A
n
tip
sy
c
h
o
tic
s
fo
r
tre
a
tm
e
n
t
o
f
d
e
liriu
m
in
h
o
sp
ita
lise
d
n
o
n
-IC
U
p
a
tie
n
ts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; DRS: Delirium Rating Scale; DRS-R98 = Delirium Rating Scale Revised 98; EPS: Extrapyramidal Symptoms; MDAS: Memorial Delirium Assessment
Scale; RR: Risk rat io; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 DRS = Delirium Rating Scale; DRS-R98 = Delirium Rating Scale -Revised 98; MDAS = Memorial Delirium Assessment Scale
2 Only 1 of the 4 trials was considered low risk of bias across all domains. Three of the four trials had blinded delirium
assessment.
3 Very high heterogeneity (97%).
4 Delirium severity was measured with dif f erent tools at variable t ime points.
5 Wide conf idence interval that included both no ef fect and benef it .
6 All included trials had risk of bias.
7 Blinded delirium assessment for two of the three trials.
8 High degree of heterogeneity (83%)
9 Delirium resolut ion was measured with dif f erent tools at variable t ime points using dif ferent thresholds.
10 Wide conf idence interval.
11 Only 1 trial had low risk of bias across all domains.
12 Low number of events.
13 All t rials at risk of bias.
14 Variable tools used to assess.
15 Few events and wide conf idence intervals.
16 Assumed risk taken f rom Tahir 2010.
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B A C K G R O U N D
Description of the condition
Delirium is a dangerous and common syndrome among hospi-
talised patients (Inouye 2006a). It is estimated to be present in 8%
to 17% of all older patients in the emergency department, and
29% to 64% of general medical and older adult inpatients (Inouye
2014). Delirium is most prevalent in frail individuals such as those
with pre-existing cognitive impairments (e.g. dementia), having
undergone surgery, or suffering an acute infection or critical illness
(Inouye 2014; Rudolph 2011; Salluh 2010).
The Diagnostic and Statistical Manual of Mental Disorders (DSM-
5) of the American Psychiatric Association defines delirium as a
complex syndrome characterised by disturbances in attention (i.e.
ability to focus, sustain or shift attention), awareness (i.e. orien-
tation), and cognition (i.e. memory, perception) not explained
by a pre-existing neurocognitive disorder (DSM-V 2013). Unlike
dementia, the onset of delirium is rapid (i.e. over the course of
hours or days); symptoms fluctuate and are typically reversible.
The symptoms of delirium are unpredictable and irregular, con-
tributing to its under-detection (Inouye 2001). Based on the pre-
dominance of type of psychomotor symptoms, delirium is cate-
gorized as hyperactive, hypoactive, or mixed (i.e. presenting with
periods of both hyper- and hypoactivity) (Cole 2009).
The cause of delirium is thought to be multifactorial, dependent
on a complex interplay of predisposing and precipitating factors
(i.e. environment and iatrogenic(i.e. caused by medical examina-
tion or treatment) (Gleason 2003; Rolfson 2002), and mitigated
or aggravated by a cascade of physiological events yet to be fully
characterised. Predisposing risk factors are numerous and include
advanced age, smoking and alcohol abuse, severe illness, and the
presence of medical comorbidities such as hypertension and de-
mentia (Gleason 2003; Inouye 1996; Inouye 2014; Rolfson 2002;
Vasilevskis 2012). Patients with multiple risk factors appear to be
sensitive to evenminor precipitating insults, whereas thosewithout
such risk factors may develop delirium only following a major in-
sult (e.g. sepsis).While the definitive cause of delirium is unknown,
evidence suggests several biological networks may interact to cause
the syndrome (Watt 2013). Postulated mechanisms include ge-
netic factors, physiological stressors (e.g. inflammation, increased
metabolism, decreased oxygenation, electrolyte imbalances), and
disruptions in neurotransmitters involved in cognitive function
(Cerejeira 2010; Inouye 2014). Several neurotransmitter systems
have been implicated (Gaudreau 2005), but a relative acetylcholine
deficiency and/or dopamine excess are most supported by current
literature (Flacker 1999; Hshieh 2008; Maclullich 2013; Trzepacz
1999; Trzepacz 2000; Young 1997; ).
Description of the intervention
Current professional society guidelines direct the diagnosis, pre-
vention, and management of delirium for patients in various hos-
pital settings (Barr 2013; British Geriatric Society 2006; NICE
2010; RCP 2006). The recommended first steps in delirium care
involve identifying and reversing potential precipitating medi-
cal conditions, mitigating environmental triggers, and minimis-
ing drug exposures. Different combinations of strategies have
been used and include resolving acute medical issues, manag-
ing pain, applying reorientation strategies, normalising the sleep-
wake cycle, ensuring safe mobilisation, and evaluating potential
drug-related causes (Fosnight 2011; Inouye 2006b; Inouye 2014;
Lundstrom 2005). Numerous classes of psychoactive drugs (e.g.
antipsychotics, benzodiazepines, opioids, alpha-2 agonists, and
cholinesterase inhibitors) have been studied for their effect on
delirium in various patient populations. However, data are incon-
sistent and practice remains largely governed by clinical circum-
stance and physician discretion. Because of the uncertainty sur-
rounding antipsychotic effectiveness in delirium, professional soci-
eties recommend limited and cautious use, and only in cases where
nonpharmacological approaches have failed and symptoms remain
distressing or dangerous, or both, to the patient or healthcare staff,
or both (American Psychiatric Association 1999; CEHSE 2006;
NICE 2010).
Antipsychotic drug exposure is associated with notable risk that
should be considering when prescribing. Studies conducted in
older adult patients have shown an approximate two-fold increase
in risk of cardiac or cerebrovascular incidents - similar in magni-
tude irrespective of antipsychotic class (i.e. typical and atypical an-
tipsychotics) - even with short term use (Gill 2007; Mittal 2011;
Ray 2009; Wang 2005). Increased mortality risk was found in one
meta-analysis (Schneider 2005) of 17 placebo-controlled trials of
atypical antipsychotics (or second generation antipsychotics) in
dementia patients. As a consequence, the US Food and Drug Ad-
ministration (FDA) issued their strictest warning label or a ’black
box’ warning for all antipsychotic drugs due to the association with
serious hazard when used in the older adult patients. A black box
warning is applied to drug labelling by the FDA when there is rea-
sonable evidence of an association of serious and, sometimes, life-
threatening adverse events. Antipsychotics have also been shown
to paradoxically worsen delirium severity in some patients (Agar
2016). These are important findings, as delirious patients are often
frail and have multiple comorbidities (Inouye 2014). Despite the
known risks and lack of strong data showing consistent benefit,
physician surveys (Carnes 2003;Meagher 2010) and observational
data (Briskman 2010; Hatta 2014) show exceedingly high use of
antipsychotics in hospitalised delirious patients (77% to 87%).
How the intervention might work
While relative excess of the neurotransmitter dopamine remains
a leading hypothesised neurochemical substrate for delirium
(Hshieh 2008; Trzepacz 1999; Trzepacz 2000; Young 1997), few
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studies have examinedneurotransmittermetabolism in the context
of delirium trajectory (Thomas 2008; Van der Cammen 2006).
The therapeutic effects of antipsychotics in delirium remain un-
known, but it is postulated their effects may be mediated through
a reduction of psychotic symptoms (also known as positive symp-
toms for patients with schizophrenia), or through sedation. There
are two types of antipsychotics: first generation, also known as typ-
ical antipsychotics, (e.g. haloperidol, chlorpromazine) and second
generation, also known as atypical antipsychotics, (e.g. quetiapine,
olanzapine, risperidone). Both groups of antipsychotics block the
brain’s dopamine receptor pathways but atypical antipsychotics
also act on serotonin receptors. Both are effective for managing
the positive symptoms in schizophrenia (e.g. psychosis, hallucina-
tions, agitation) but atypical antipsychotics also improve the neg-
ative symptoms such as emotional and social withdrawal.
Antipsychotics are thought to helpwith the psychotic symptomsof
delirium but have also been shown useful in individuals who have
hypoactive symptoms (Boettger 2011a; Boettger 2011b; Breitbart
2002b; Ito 2007; Platt 1994). Studies investigating changes in in-
dividual delirium symptomatology in the context of antipsychotic
treatment have yielded conflicting results. It appears both cogni-
tive and noncognitive symptoms may improve to varying extents.
Specifically, where some studies demonstrate a similar trajectory
for both types of symptoms (Breitbart 1996; Kim 2003; Leonard
2015; Meagher 2012; Parellada 2004; Sasaki 2003), others show a
more rapid recovery of noncognitive disturbances (e.g. inattention
and disorientation) (Devlin 2011; Tahir 2010).
Why it is important to do this review
Studies have shown an association between delirium and adverse
outcomes such as prolonged length of hospital stay, increased hos-
pital mortality, and higher rates of hospital readmission, institu-
tionalisation, and functional and cognitive decline, even after ad-
justment for comorbidities and illness severity (Buurman 2011;
Han 2010; Inouye 1998; Kakuma 2003; Leslie 2005; Levkoff
1992; McCusker 2001; McCusker 2002; Pitkala 2005; Pompei
1994; Rizzo 2001; Witlox 2010). Delirium is also known to cause
distress to patients, their families, and clinical staff (Breitbart
2002a; Bruera 2009; Buss 2007; Cohen 2009; Morita 2004;
Partridge 2013). The economic burden of delirium is significant: a
delirious state is associated with a 20% increased risk of prolonged
hospitalisation, translating to an average of more than 8 to 10 ad-
ditional days in hospital (Leslie 2008; McCusker 2003; OECD
2012; WHO 2012). The annual cost of delirium has been esti-
mated at more than USD 164 billion (Leslie 2008) in the United
States, and over EUR 182 billion in 18 combined European coun-
tries (OECD 2012; WHO 2012). Delirium in hospitalised pa-
tients clearly represents a substantial public health concern.
Because of its myriad iatrogenic factors (e.g. medications, immo-
bilisation, catheterisation, and sleep impairment) (Inouye 1999),
delirium is considered a preventable adverse event (Gillick 1982;
Rothschild 2000) and is used as an indicator of quality of care
in the elderly (IHI 2014; Safer Healthcare Now 2005). Notwith-
standing, not all cases of delirium can be prevented and the im-
petus to determine safe and effective treatment strategies remains
important for clinicians, patients, families, and the healthcare sys-
tem.
In clinical practice, antipsychotics are often the first pharmaco-
logical treatment initiated, despite conflicting evidence support-
ing their efficacy and reports indicating increased risk of serious
adverse events, especially in the frail elderly (Gill 2007; Mittal
2011; Ray 2009; Wang 2005). Herein, we have updated the pre-
viously published Cochrane Review (Lonergan 2007). An update
was warranted, given the high prevalence of hospital delirium, its
associated clinical and financial burden, and the publication of
new studies in the decade since the original publication.
O B J E C T I V E S
Our primary objective was to assess the efficacy of antipsychotics
versus nonantipsychotics or placebo on the duration of delirium
in hospitalised adults (excluding critically ill populations).
Our secondary objectives were to compare the efficacy of 1) an-
tipsychotics versus nonantipsychotics or placebo on a) delirium
severity and b) delirium resolution, c) mortality, d) hospital length
of stay, e) discharge disposition, f ) health-related quality of life,
and g) adverse effects (e.g. sudden cardiac death, QTc prolonga-
tion (i.e. increased time between the Q wave and the end of the
T wave in the heart’s electrical cycle), seizures, use of physical re-
straints); and 2) atypical versus typical antipsychotics for reducing
a) delirium duration, b) delirium severity, and c) resolution, d)
mortality, e) hospital length of stay, f ) discharge disposition, g)
health-related quality of life outcomes, and h) adverse effects (e.g.
sudden cardiac death, QT prolongation, seizures, use of physical
restraints).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all trials using a randomised or quasi-randomised
design that compared an antipsychotic to a nonantipsychotic (e.g.
alternative drug class such as benzodiazepines), placebo, or second
antipsychotic of a different generation (secondary outcome) for
the treatment of delirium.We excluded nonrandomised and cross-
over interventional studies as well as observational studies.
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Types of participants
We included studies of adults (> 16 years of age) diagnosed with
delirium and treated in an acute care setting. We excluded trials
with a primary aim of treating delirium secondary to substance/
alcohol-induced withdrawal, recruiting participants solely in out-
patient, psychiatric, or long-term care settings, or in an inten-
sive care unit (a high intensity unit). A delirium diagnosis had to
have been made by a trained individual (e.g. psychiatrist, geria-
trician), through formal assessment using Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM) criteria (DSM-IV 1994;
DSM-IV-TR 2000; DSM-V 2013), or by a validated delirium
screening tool (e.g. Inouye 1990; Neelon 1996; Traube 2014).We
excluded studies where antipsychotics were evaluated for delirium
prevention.
Types of interventions
To answer our primary objective, we included studies comparing
an antipsychotic to a nonantipsychotic drug (e.g. alternative drug
class such as benzodiazepine) or placebo. We permitted inclusion
of trials that had a nonantipsychotic group without a placebo
group, as no drug has been consistently shown to be more effective
than placebo. Therefore, a nonantipsychotic group was thought
of as a placebo. We also included studies comparing a typical an-
tipsychotic to an atypical antipsychotic to answer our secondary
objectives. When antipsychotics are initiated to manage delirium
symptoms in clinical practice, clinicians often select atypical an-
tipsychotics over a typical antipsychotic. Therefore, we included
trials that compared the two classes of antipsychotics, irrespective
of inclusion of a placebo group in the study. We did not include
trials that only examined two or more antipsychotics of the same
class without an alternative drug or alternative antipsychotic class,
or placebo.
A priori, we anticipated the selection of comparison treatments
would be variable and that nonantipsychotic agentsmight include:
alpha-2 agonists, antidepressants, benzodiazepines, cholinesterase
inhibitors, melatonin or melatonin agonists, or opioids. No re-
strictions on dose, frequency, intensity, or duration of therapywere
applied.
Types of outcome measures
We selected outcomes pertaining to the benefits and hazards of
antipsychotic drugs that are meaningful to hospitalised patients
with delirium, their families, and health care professionals.
Primary outcome
1. Total duration of delirium (days)
Secondary outcomes
1. Delirium severity, assessed by validated instruments such as
Delirium Rating Scale (e.g. DRS or DRS-98-R) (Trzepacz 1988;
Trzepacz 2001) and Memorial Delirium Assessment Scale
(MDAS) (Breitbart 1997) (mean change from baseline to end of
study period)
2. Delirium resolution (defined as reduction of DRS or DRS-
98-R below a target set by the authors or complete resolution of
symptoms)
3. Mortality
4. Hospital length of stay (days)
5. Hospital discharge disposition (e.g. rehabilitation, chronic
care facility, home)
6. Health-related quality of life (as reported by study authors)
7. Adverse events as defined by the study authors (e.g.
prolongation of the QTc interval (QT interval measures the time
between the start of the Q wave and the end of the T wave in the
heart’s electrical cycle), sudden cardiac death, cerebral vascular
events, seizures, extrapyramidal effects, use of physical restraints,
long-term cognitive impairment (e.g. change in Mini Mental
Status Exam or as reported by study authors)).
Search methods for identification of studies
Electronic searches
Electronic search strategies were developed and tested through an
iterative process by an experienced information scientist in con-
sultation with our team. The concepts encompassed in the search
strategy included: 1) population (i.e. patients in acute care settings
diagnosedwith delirium), 2) intervention (antipsychotics), and (3)
comparators. Test searches were performed at various stages (i.e.
before and after combining search terms) to ascertain the number
of hits and verify capture of studies known to meet the inclusion
criteria. We searched the following electronic databases from their
respective dates of inception to July 20, 2017: MEDLINE (Ovid
SP) (1946 to July 20, 2017); Embase (Ovid SP) (1947 to 2017
Week 28); Cochrane EBM Reviews - Central Register of Con-
trolled Trials (CENTRAL) (July 20, 2017); CINAHL (EBSCO-
host) (1982 to July 20, 2017); Thomson Reuters Web of Science
(July 20, 2017) and Latin American and Caribbean Health Sci-
ences Literature (LILACS) (1986 to July 20, 2017). We searched
the Database of Abstracts of Reviews of Effects (DARE) and the
Health Technology Assessment Database (HTADatabase) to their
second quarter of 2017 for published reviews on the review topic.
Specific details regarding search strategies can be found in the ap-
pendices (Appendix 1; Appendix 2; Appendix 3; Appendix 4; Ap-
pendix 5; Appendix 6; Appendix 7; Appendix 8). Search strategies
utilised a combination of controlled vocabulary and keywords,
and vocabulary and syntax were adjusted for each database. We
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limited our search to randomised controlled trials, systematic re-
views, and meta-analyses. We applied a filter to limit to humans,
and no language restriction was imposed.
Searching other resources
We searched conference proceedings using theWeb of Science ISI
Proceedings (2004 to July 2017).We searched for unpublished and
ongoing trials on the followingweb sites: 1. www.clinicaltrials.gov/
; and 2. www.who.int/trialsearch. We handsearched the reference
lists of all retrieved studies for additional relevant studies. Cor-
responding authors of eligible trials and experts in the field were
contacted to identify other potential studies. The Internet was
searched using the Google search engine to find additional un-
published evidence.
Data collection and analysis
Selection of studies
Each title and abstract identified from the electronic and manual
searches were independently examined by two authors (LB, LR)
to identify potentially eligible trials. Selected trials were screened
for relevance against defined inclusion and exclusion criteria (Ap-
pendix 9). References were organised in the reference manager
Endnote (Version X6, Thomson Reuters, Carlsbad, CA, USA)
(Endnotes) with reasons for exclusion documented in the notes
field. The studies identified as eligible were examined indepen-
dently and in full to confirm inclusion. Disagreements were re-
solved by discussion with an independent arbiter (NS).
Data extraction and management
We did not blind data extractors to the identity of study authors
because of our familiarity with the literature on the topic. Two
authors (LB, LR) revised and piloted the previous data extraction
form to ensure capture of all relevant data. Once the included tri-
als were identified and agreed upon, four authors independently
extracted data. Each study was independently examined by a pair
of authors (SM and MP; JL and CB). All data extraction was con-
firmed by a third author (LB). Any identified duplicate reports
from a single study were assembled as one reference. The ’Char-
acteristics of included studies’ table (Characteristics of included
studies) was created using Review Manager (RevMan 2014).
As we were interested in determining if the intervention reduced
the overall severity or burden of delirium, we extracted and used
the highest recorded score for delirium severity for both the inter-
vention and control armwhenmultiple time points were available.
For example, if DRS-98-R was scored multiple times after study
enrolment, then we selected only the highest of those scores for
our analyses.
Assessment of risk of bias in included studies
Each data extractor independently assessed the risk of bias of each
study, which was then verified by another author (NS). These
assessments were done via a domain-based evaluation as recom-
mended by The Cochrane Collaboration (Higgins 2011). The do-
mains are:
1. Random sequence generation (i.e. selection bias);
2. Allocation concealment (i.e. selection bias);
3. Blinding of participants and personnel (i.e. performance bias);
4. Blinding of outcomes assessment (i.e. detection bias);
5. Incomplete outcome data (i.e. attrition bias);
6. Selective reporting; and
7. Other potential sources of bias.
For each domain, we assessed the risk of bias as ’low’, ’high’, or
’unclear’. Unclear risk was assigned if insufficient detail was re-
ported, or if what happened in the study was known but the risk
of bias was unclear or unknown. Once risk of bias assessment was
agreed upon, each study was categorised as follows:
Low risk of bias: studies where all domains were considered ’low’
risk of bias;
High risk of bias: studies where one or more domains were con-
sidered to be ’high’ risk of bias; and
Unclear risk of bias: studies where one ormore domains was scored
as ’unclear’ risk of bias.
We generated a ’risk of bias’ graph figure and summary figure upon
completion of assessment in Review Manager (RevMan 2014).
Measures of treatment effect
We used risk ratios (RRs) as measures of treatment effect for di-
chotomous outcomes. We used between-group mean differences
(MD or SMD) and standard deviations for continuous outcomes.
Unit of analysis issues
We used data from individual participants as the unit of analysis
in each trial arm. As anticipated, all included trials were parallel
group design, so adjustments were not necessary for clustering.
Dealing with missing data
When necessary, we contacted the corresponding authors to clar-
ify issues related to data reporting and/or to obtain further study
details. Missing data and dropout rates were assessed for each in-
cluded study and reported in the risk of bias table. For missing data
(e.g. standard deviations associated with continuous outcomes)
we sent the corresponding author a maximum of three emails to
request the missing information. If this failed, we used established
methods to impute standard deviation values.When onlymedians
and interquartile ranges (IQR) or ranges were reported and not
available from study authors we assumed the median value to be
equal to the mean to permit utilisation of all of data identified. To
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estimate standard deviations we used ’IQR/1.35’ or ’range/4’ (for
studies with n < 70) and ’range/6’ for studies with n > 70.
Assessment of heterogeneity
Heterogeneity canbe the result of anunevendistributionof impor-
tant clinical and methodological effect modifiers across studies or
across comparisons. We assessed each trial for statistical and clini-
cal heterogeneity. We evaluated statistical heterogeneity using the
I² statistic and the X² test of homogeneity with p < 0.05 indicative
of heterogeneity.We applied the categorisation values described by
Higgins: low (0% to 40%), moderate (30% to 60%), substantial
(50% to 90%), and considerable (75% to 100%) heterogeneity
(Higgins 2003). We qualitatively assessed clinical heterogeneity
by examining delirium management strategies in each trial (e.g.
treatment dose, use of rescue medications or chemical restraint
when primary treatment fails, non-drug treatment strategies such
as noise reduction or improving the day-night cycle, medications
avoided, physical restraint) as well as country of study origin, year
of study publication, and single centre versus multicentre study.
Assessment of reporting biases
We planned construction and visual inspection of funnel plots to
assess for possible publication bias in ReviewManager 5 (RevMan
2014) for analyses where > 10 studies were available. We planned
to test for funnel plot asymmetry using the test proposed by Egger
(Egger 1997), but there were insufficient studies to proceed with
this step.
Data synthesis
Two authors (LB, BH) entered data in Revman 5 (RevMan 2014).
Three authors (LB, BH, DF) conducted the analyses and reported
summary statistics for the data. We synthesised dichotomous data
with risk ratios (RR) and 95% confidence intervals (CI) using the
Mantel-Haenszel random-effects model (REM) to allow for ad-
justments that incorporated variation both within and between
studies (DeMets 1987). Continuous outcomes (e.g. duration of
delirium, hospital length of stay) were synthesised as pooled mean
differences (MD), or standardisedmeandifferences (SMD) (where
measurement scales varied across studies) with 95%CIs using ran-
dom-effects inverse variance methods. For continuous end points
that involved an analysis of changes from baseline in each group,
where necessary, a correlation coefficient was used to estimate the
standard deviation associated with mean change in each group.
We considered P < 0.05 (two sided) as significant.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses to determine if the
efficacy and safety of antipsychotics were influenced by: 1) age (<
65 versus ≥ 65 years); and 2) history of dementia.
Sensitivity analysis
We conducted sensitivity analyses to explore the effect on the
pooled estimate of including only studies at low risk of bias in all
but one domain and those that included a placebo group.
Data presentation - ’Summary of findings’ table
We used the GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) (Guyatt 2008) approach to assess
the quality of the supporting evidence associatedwith selected out-
comes. The findings are presented using a ’Summary of findings’
(SoF) table summarising the amount of data identified, within-
study risk of bias, directness of evidence, data heterogeneity, and
precision of effect estimates. The SoF table was generated using
GRADEpro software (GRADEpro GDT 2015). We selected the
following outcomes a priori as being relevant for clinical practice:
duration of delirium, severity of delirium, delirium resolution,
mortality, hospital length of stay, and incidence of adverse effects.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies
We included randomised and quasi-randomised controlled trials
of adult hospitalised non-ICU patients treated for delirium. We
identified eligible trials with an intervention arm including an an-
tipsychotic drug.Deliriummanagement for control arms included
a nonantipsychotic drug (e.g. alternative drug class such as ben-
zodiazepines), placebo, or secondary antipsychotic of alternative
class (i.e. typical versus atypical).
Results of the search
We reported the results of the search outlined above in Figure
1. The initial electronic database query yielded 21,599 citations.
We retrieved 132 references for full-text assessment. We identi-
fied nine studies meeting inclusion criteria, and excluded the re-
maining 123. We classified four studies as awaiting classification
(Characteristics of studies awaiting classification): one full publi-
cation (Nakamura 1997) and three conference abstracts (Djokic
2008; Jung Jin 2009; Lee 2013). We identified two trial registra-
tions for further consideration. We classified one study as meeting
inclusion criteria and ongoing (NCT02345902; Characteristics of
ongoing studies), and the other as a duplicate of a study published
in full and already included in the review (Hu2004;Characteristics
of included studies).When this latter study was translated into the
English language, the primary author’s first and last names were
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reversed. We identified this upon closer inspection and classified
the second trial registration as a duplicate.
Figure 1. PRISMA flow diagram of search results.
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Included studies
See: Characteristics of included studies table.
We included nine randomised trials with a total of 727 partic-
ipants (Agar 2016; Breitbart 1996; Grover 2011; Grover 2016;
Han 2004;Hu 2004; Lin 2008;Maneeton 2013; Tahir 2010).We
provide detailed descriptions of each study in theCharacteristics of
included studies table. Sample sizes of trials ranged from 24 (Han
2004) to 247 (Agar 2016) participants. Four of the identified trials
included more than two study arms (Agar 2016; Breitbart 1996;
Grover 2011; Hu 2004). Only a single study (Agar 2016) included
multiple sites; all others had a single centre design. The trials
were conducted in a number of countries: Australia (Agar 2016);
China (Hu 2004); India (Grover 2011; Grover 2016); Korea (Han
2004); Taiwan (Lin 2008); Thailand (Maneeton 2013); United
States (Breitbart 1996); and United Kingdom (Tahir 2010). All
studies included hospitalised patient populations: medical only
(Breitbart 1996; Hu 2004; Maneeton 2013), mixed medical and
surgical (Grover 2011; Grover 2016; Han 2004; Tahir 2010), and
palliative (Agar 2016; Lin 2008). One trial specifically evaluated
participants with dementia (Hu 2004). The mean reported age
of participants across trials ranged from 44 (Grover 2011) to 84
(Tahir 2010) years; 22% (Grover 2016) to 71% (Tahir 2010) of
participants were female. Six studies (Agar 2016; Breitbart 1996;
Grover 2011; Han 2004; Maneeton 2013; Tahir 2010) provided
details of funding sources; one trial received pharmaceutical in-
dustry funding (Tahir 2010).
Four trials compared one or more antipsychotic drug to a nonan-
tipsychotic or placebo (Agar 2016; Breitbart 1996; Hu 2004;
Tahir 2010), three of these trials included a placebo group (Agar
2016; Hu 2004; Tahir 2010), and one compared antipsychotics
(haloperidol or chlorpromazine) to the benzodiazepine lorazepam
(Breitbart 1996). Seven trials compared a typical to an atypical
antipsychotic drug (Agar 2016; Grover 2011; Grover 2016; Han
2004; Hu 2004; Lin 2008; Maneeton 2013). Of these, two (Agar
2016;Hu 2004) also included a placebo group (i.e. 3-arm studies).
Haloperidol was the most commonly studied antipsychotic, eval-
uated in all but one trial (Tahir 2010). All trials titrated study
drug based on symptom response. The duration of therapy was
variable and included three- (Agar 2016), six- (Breitbart 1996;
Grover 2011; Grover 2016), seven- (Han 2004; Hu 2004; Lin
2008;Maneeton 2013), and ten-day (Tahir 2010) administration.
The use of rescue drugs such as benzodiazepines for breakthrough
agitation was permitted in five trials (Agar 2016; Grover 2011;
Grover 2016; Lin 2008; Tahir 2010), prohibited in three (Hu
2004; Maneeton 2013; Breitbart 1996), and not reported in one
(Han 2004). No trial reported on the use of physical restraints or
sitters/personal attendants.
All trials used some combination of DSM criteria (DSM-IV 1994;
DSM-IV-TR 2000; DSM-V 2013) or the Confusion Assessment
Method (CAM) (Inouye 1990), or both, to detect delirium for
study enrolment; subjects in all included studies were screened
daily. Cointerventions for delirium management such as reori-
entation, family support, and environmental manipulations were
used in five studies (Agar 2016; Grover 2011; Grover 2016; Hu
2004; Maneeton 2013) and not reported in the remaining four
(Breitbart 1996; Han 2004; Lin 2008; Tahir 2010).
Excluded studies
See: Characteristics of excluded studies table.
We excluded ten randomised trials because the population of in-
terest was limited to critically ill individuals (Al Qadheeb 2016;
Atalan2013; Bakri 2015;Devlin 2010;Girard 2010;Hakim2012;
Page 2013; Reade 2009; Reade 2016; Skrobik 2014). These tri-
als are included in the Cochrane protocol ACE311 ’Pharmaco-
logical interventions for the treatment of delirium in critically ill
patients’ (Burry 2015) using the operational definition of criti-
cal care/intensive care applied by this Cochrane division. We ex-
cluded five additional studies (Jung 2009; Jung 2010; Kim 2010;
Lee 2005; Sakong 2010) because of lack of adequate comparator
group. These five studies evaluated the effect of antipsychotic(s)
on hospitalised, non-critically ill participants with delirium but
did not include a nonantipsychotic arm or they compared two an-
tipsychotics of the same class (e.g. atypical versus atypical) without
a third group that included a placebo or nonantipsychotic drug.
Risk of bias in included studies
The ’Risk of bias’ tables present details on the performance of the
included trials for each risk of bias domain. A summary of our
judgement of the methodological quality of the included studies
is depicted in Figure 2 and Figure 3. Only one study (Agar 2016)
was scored as low risk of bias across all domains. The remaining
studies scored unclear risk of bias in one or more domains, or had
a combination of unclear and high risk of bias across multiple
domains. In particular, Hu 2004 scored high risk of bias across
two domains..
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation (selection bias):
Five studies (Agar 2016; Breitbart 1996; Grover 2016; Maneeton
2013; Tahir 2010) specified the use of randomisation tables. The
method of sequence generationwas not reported in themanuscript
or available from the authors for the remaining four trials (Grover
2011; Han 2004; Hu 2004; Lin 2008), therefore, we scored these
as unclear risk of bias.
We judged five studies (Agar 2016; Breitbart 1996; Grover 2011;
Maneeton 2013; Tahir 2010) to have low risk of selection bias
based on their allocation concealmentmeasures. Two studies (Agar
2016; Tahir 2010) used sealed opaque envelopes and another used
a pharmacist (Breitbart 1996) not otherwise involved in patient
care to dispense the study drug. In Grover 2011, the randomisa-
tion and study drug dose adjustments were carried out by one in-
vestigator who did not assess outcomes. In Maneeton 2013, iden-
tical capsules were used to dispense the study drug. We judged the
remaining studies (Grover 2016; Han 2004; Hu 2004; Lin 2008)
to have unclear risk of selection bias due to insufficient or no detail
to assess allocation concealment.
Blinding (performance bias and detection bias):
We judged all studies but one (Hu 2004) to have low risk of
blinding bias. Four studies (Agar 2016; Breitbart 1996; Maneeton
2013; Tahir 2010) were double-blinded. A single-blind design
was used in three studies (Grover 2011; Grover 2016; Lin 2008)
that specifically reported the delirium assessment was performed
by a standard blinded assessor. Although Han 2004 study was
stated as double-blind, this was unlikely as the study drugs were
not stated to be identical. However, one psychiatrist, blind to
treatment group, performed the delirium assessments. We judged
Hu 2004 study to have high risk of bias as it was not possible to
blind subcutaneous haloperidol and enteral olanzapine, unless a
double-dummy design was used. As no details were provided, we
assumed the drug formulation was unblinded.
Incomplete outcome data (attrition bias):
We judged three studies (Agar 2016;Maneeton 2013; Tahir 2010)
to have low risk of attrition bias because all used intention-to-treat
analysis or had no missing data. We judged one study (Breitbart
1996) to have unclear risk of attrition bias. The lorazepam arm
in Breitbart 1996 was discontinued early due to adverse events,
but available data were used in the analysis. We judged five studies
(Grover 2011; Grover 2016; Han 2004; Hu 2004; Lin 2008) to
have high risk of attrition bias due to incomplete data or missing
participants. In Grover 2011, ten participants did not complete
the study; six could not be assessed at least once due to worsen-
ing clinical status, and four left hospital against medical advice.
In Grover 2016, seven participants did not complete the study;
four could not be assessed because they left against medical ad-
vice, one quetiapine participant received injectable haloperidol for
symptommanagement, and two could not be started on the study
drug because of worsening clinical status. In the Han 2004 study,
four participants did not complete the study, three due to medical
complications and one due to spousal refusal; these participants
were not included in the analysis. The Hu 2004 study made no
mention of how attrition was factored into the statistical analysis
despite reporting five participants not completing the study (one
death, one leaving due to financial reasons, one discharge, and two
withdrawals). Lastly, Lin 2008 did not report the total number of
participants enrolled or lost to follow-up.
Selective reporting (reporting bias):
We found four trials were registered (Agar 2016; Hu 2004;
Maneeton 2013; Tahir 2010) and, therefore, it was possible to
examine reporting bias. These trials were deemed at low risk of
bias. For the remaining studies, we scored them as at unclear risk
of bias.
Other potential sources of bias:
Referral bias was a potential issue for four trials (Grover 2011;
Grover 2016; Lin 2008; Maneeton 2013) where participants were
recruited specifically from referrals to psychiatry services. Sample
size calculations were not provided for five trials (Breitbart 1996;
Grover 2011; Grover 2016; Han 2004; Lin 2008) so it was un-
clear if adequate power was attained. Two trials (Maneeton 2013;
Tahir 2010) did not meet the required sample size. In one study
(Maneeton 2013), 34 participants per group were needed to have
adequate power to detect a meaningful difference in DRS-R-98
score; however, the final numbers were 24 and 28 participants in
the quetiapine and haloperidol groups, respectively. The sample
size calculation was reported in the second study (Tahir 2010),
however the trial was stopped early at the request of the man-
ufacturer due to the FDA’s concern on the use of antipsychotic
medication in the elderly. The study was therefore underpowered.
Finally, one included study (Tahir 2010) permitted lorazepam in-
jection for rescue, but all participants who received it were in the
quetiapine group. It was unclear how lorazepam administration in
only one group would influence results.
Effects of interventions
See: Summary of findings for the main comparison
Antipsychotics versus nonantipsychotics or placebo for the
treatment of delirium in hospitalised patients; Summary of
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findings 2 Typical versus atypical antipsychotics for treatment of
delirium in hospitalised patients
See: Summary of findings for the main comparison; Summary of
findings 2
We present below our analyses for our primary outcome, dura-
tion of delirium, and our secondary outcomes of severity of delir-
ium, delirium resolution, mortality, hospital length of stay and
discharge disposition, health-related quality of life, and adverse
events. For each outcome, we present first the results for the com-
parison of an antipsychotic versus nonantipsychotic or placebo
and then the class comparison of typical versus atypical antipsy-
chotic.
Duration of delirium
Antipsychotic versus nonantipsychotic drug or placebo
Duration of delirium was not reported for any of the four trials
comparing an antipsychotic to a nonantipsychotic drug.
Typical versus atypical antipsychotic drug
Duration of delirium was not reported for any trial comparing
typical versus atypical antipsychotics drugs.
Delirium severity
Antipsychotic versus nonantipsychotic drug or placebo
Delirium severity was reported for four studies (Agar 2016;
Breitbart 1996; Hu 2004; Tahir 2010). Delirium severity was
scored with different tools: the DRS (Breitbart 1996; Hu 2004),
DRS-98-R (Tahir 2010), and MDAS (Agar 2016), assessed at
baseline and at the end of the study. Three of the studies were
double-blind so delirium assessments were blinded. The pooled
result indicated no difference in delirium severity (SMD -1.08,
95%CI -2.55 to 0.39; four studies; 494 participants; Analysis 1.1;
Figure 4). There was substantial heterogeneity (I² = 97%). We
assessed this as very low-quality evidence (downgraded due to risk
of bias, inconsistency and imprecision). For sensitivity analyses,
we repeated the analysis by i) removing trial(s) that did not have
a placebo group (Breitbart 1996) (SMD -0.89, 95% CI -2.64 to
0.86; three studies; 464 participants; I² = 98%; Analysis 1.2) and
ii) including only trials with low risk of bias (SMD 0.03, 95% CI
-0.22 to 0.27; 289 participants; I² = 0%; Analysis 1.3).
Figure 4. Forest plot of comparison: 2 severity of delirium, outcome: 2.1 antipsychotic versus no
antipsychotic.
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Typical versus atypical antipsychotic drug
Seven studies (Agar 2016; Grover 2011; Grover 2016; Han 2004;
Hu 2004; Lin 2008; Maneeton 2013) reported this outcome. All
but one trial (Han 2004) had delirium assessment by a psychiatrist
or nurse blinded to the status of treatment. Delirium severity was
scored with the DRS (Han 2004; Hu 2004; Lin 2008), DRS-
98-R (Grover 2011; Grover 2016; Maneeton 2013) and MDAS
(Agar 2016), assessed at baseline and at the end of study treatment.
The pooled result showed no difference in delirium severity (SMD
-0.17, 95% CI -0.37 to 0.02; 542 participants, Analysis 1.4;
Figure 5). There was a low degree of heterogeneity (I² = 16%). We
assessed this as low-quality evidence (downgraded due to risk of
bias, inconsistency). It was not feasible to conduct the sensitivity
analysis including only trials at low risk of bias.
Figure 5. Forest plot of comparison: 1 severity of delirium, outcome: 1.4 atypical antipsychotic versus
typical antipsychotic.
Delirium resolution
Antipsychotic versus nonantipsychotic drug or placebo
Delirium resolutionwas reported for three studies (Breitbart 1996;
Hu 2004; Tahir 2010). The definition of resolution applied in the
trials varied: complete alleviation of symptoms (Hu 2004), allevi-
ation of symptoms to below an unspecified diagnostic threshold
(Breitbart 1996), and a cutoff of DRS-R98 < 15 on day 7 (Tahir
2010). Two of the studies were double-blind so delirium assess-
ments were blinded. The pooled result indicated no significant
difference in overall delirium resolution (RR 0.95, 95% CI 0.30
to 2.98; three studies, 247 participants; Analysis 2.1; Figure 6).
There was a high degree of heterogeneity (I² = 83%). We assessed
this as very low-quality evidence (downgraded due to risk of bias,
inconsistency, imprecision). As a sensitivity analysis, we (Analysis
2.2) included only trials with a placebo group (Hu 2004; Tahir
2010). The pooled result indicated no significant difference in
overall delirium resolution (RR 1.43, 95% CI 0.58 to 3.54; two
studies; 217 participants) but with less heterogeneity (I² = 30%).
It was not feasible to conduct the sensitivity analysis including
only trials at low risk of bias.
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Figure 6. Forest plot of comparison: 3 resolution, outcome: 3.1 antipsychotic versus no antipsychotic.
Typical versus atypical antipsychotic drug
Delirium resolution was reported for five studies (Grover 2011;
Grover 2016; Han 2004; Hu 2004; Maneeton 2013). The defi-
nition of resolution varied in the trials: DRS-R98 < 10 (Grover
2011; Grover 2016), DRS-R98 < 12 (Maneeton 2013), MDAS
< 13 (Han 2004), and complete alleviation of symptoms (Hu
2004). Four of the trials (Grover 2011; Grover 2016; Han 2004;
Maneeton 2013) were blinded studies and had blinded delirium
assessments. The pooled result indicated no significant difference
in overall delirium resolution (RR 1.10, 95%CI 0.79 to 1.52; 349
participants; Analysis 2.3; Figure 7). There was a low degree of
heterogeneity (I² = 2%). We assessed this as low-quality evidence
(downgraded due to risk of bias, inconsistency). It was not feasible
to conduct the sensitivity analysis including only trials at low risk
of bias.
Figure 7. Forest plot of comparison: 2 resolution, outcome: 2.3 atypical antipsychotic versus typical
antipsychotic.
Mortality
Antipsychotic versus nonantipsychotic drug or placebo
Mortality was reported for three studies (Agar 2016; Breitbart
1996; Tahir 2010). The end point was measured at study day
three (Agar 2016), within one week of study completion (Breitbart
1996), and at day 30 (Tahir 2010). The pooled result indicated no
statistical difference in mortality (RR 1.29, 95% CI 0.73 to 2.27;
three studies, 319 participants; Analysis 3.1; Figure 8). There was
a low degree of heterogeneity (I² = 0%). We assessed this as low-
quality evidence (downgraded due to risk of bias, imprecision).
We conducted a sensitivity analysis with only trials that included
a placebo group (Analysis 3.2). The pooled result indicated no
statistical difference in mortality (RR 1.41, 95% CI 0.75 to 2.66;
two studies; 289 participants; I² = 0%).
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Figure 8. Forest plot of comparison: 3 mortality, outcome: 3.1 antipsychotic versus no antipsychotic.
Typical versus atypical antipsychotic drug
Mortality was reported for four studies (Agar 2016; Grover 2011;
Grover 2016; Maneeton 2013). Time to end point was measured
at study day three (Agar 2016) and within one week of study en-
rolment (Grover 2011; Grover 2016; Maneeton 2013). Mortality
was very low and no deaths were reported in two studies (Grover
2011; Grover 2016). The pooled result indicated no statistical dif-
ference in overall mortality (RR 1.71, 95% CI 0.82 to 3.35; four
studies; 342 participants; Analysis 3.3; Figure 9). There was a low
degree of heterogeneity (I² = 0%). We assessed this as low-quality
evidence (downgraded due to risk of bias, imprecision).
Figure 9. Forest plot of comparison: 3 mortality, outcome: 3.3 atypical antipsychotic versus typical
antipsychotic.
Hospital length of stay (days)
Antipsychotic versus nonantipsychotic drug or placebo
No trials reported hospital length of stay, and attempts to obtain
data from corresponding study authors proved unsuccessful.
Typical versus atypical antipsychotic drug
No trials reported hospital length of stay, and attempts to obtain
data from corresponding study authors proved unsuccessful.
Hospital discharge disposition
Antipsychotic versus nonantipsychotic drug or placebo
No trials reported hospital discharge disposition, and attempts to
obtain data from corresponding study authors proved unsuccess-
ful.
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Typical versus atypical antipsychotic drug
No trials reported hospital discharge disposition, and attempts to
obtain data from corresponding study authors proved unsuccess-
ful.
Health-related quality of life
Antipsychotic versus nonantipsychotic drug or placebo
No trials reported health-related quality of life, and attempts to
obtain data from corresponding study authors proved unsuccess-
ful.
Typical versus atypical antipsychotic drug
No trials reported health-related quality of life and attempts to ob-
tain data from corresponding study authors proved unsuccessful.
Adverse events
Antipsychotic versus nonantipsychotic drug or placebo
No trials reported the use of physical restraints, long-term cogni-
tivemeasures, or incidence of seizures, cerebrovascular events, sud-
den cardiac death or QTc abnormalities. Extrapyramidal symp-
toms (EPS) were reported for three studies (Breitbart 1996; Hu
2004; Tahir 2010). EPS was assessed using the Extrapyramidal
Symptom Rating Scale in two trials (Breitbart 1996; Hu 2004),
and the method was not reported in the other trial (Tahir 2010).
The overall number of reported EPS events was low in the trials.
The pooled result indicated the risk of EPS with antipsychotics
was not statistically increased (RR 1.70, 95% CI 0.04 to 65.57;
247 participants; Analysis 4.1; Figure 10). There was substantial
heterogeneity (I² = 77%). We assessed the evidence as very low-
quality evidence (downgraded due to risk of bias, inconsistency,
imprecision). One additional study (Agar 2016) reported signif-
icantly greater mean extrapyramidal effects in risperidone versus
placebo-treated participants using mixed effects modelling, with-
out specifying the actual summary measure used (0.73, 95% CI
0.09 to 1.37, P = 0.03) and haloperidol versus placebo-treated
(0.79, 95% CI 0.17 to 1.41, P = 0.01) participants on each study
day. Raw data were not available, thus, we were unable to pool
these data with the other trials.
Figure 10. Forest plot of comparison: 4 adverse event, outcome: 4.1 antipsychotic versus no antipsychotic
(EPS).
Typical versus atypical antipsychotic drug
No trials reported the use of physical restraints, long-term cogni-
tivemeasures, cerebrovascular events, sudden cardiac death orQTc
abnormalities. One trial (Maneeton 2013) reported on seizures
with one seizure in the quetiapine group and no seizures in the
haloperidol group. This trial also reported arrhythmias with one
AV block episode in the haloperidol group and no events in the
quetiapine group. Two trials (Hu 2004;Maneeton 2013) reported
EPS symptoms. EPS was assessed using the Extrapyramidal Symp-
tom Rating Scale in one trial (Hu 2004) and the other withMSAS
(Maneeton 2013). The overall number of participants experienc-
ing any EPS symptoms was low. The pooled results showed no sta-
tistical increased risk of EPS with typical antipsychotics compared
to atypical antipsychotics (RR 12.16, 95% CI 0.55 to 269.52;
two studies; 198 participants; Analysis 4.2; Figure 11). There was
a moderate degree of heterogeneity (I² = 54%). We assessed the
evidence as very low-quality evidence (downgraded due to risk of
bias, inconsistency, imprecision).
21Antipsychotics for treatment of delirium in hospitalised non-ICU patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 11. Forest plot of comparison: 4 adverse event, outcome: 4.2 atypical antipsychotic versus typical
antipsychotic (EPS).
Subgroup analysis and investigation of heterogeneity
We intended to conduct subgroup analyses exploring the effects
of controlling for age and history of dementia. However, due to
the small number of included studies and lack of relevant data,
these analyses could not be conducted. We found substantial het-
erogeneity in analysis 1.1 (Analysis 1.1), 1.2 (Analysis 1.2) and 4.1
(Analysis 4.1). When we removed the studies not at low risk of
bias (Breitbart 1996 and Hu 2004; Analysis 1.3) there is no longer
such variability. We believe the use of different tools to measure
the outcome may potentially explain the variation identified.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Typical versusAtypical antipsychotics for treatment of delirium in hospitalised patients
Patient or population: delirious pat ients
Settings: hospital wards, not ICU
Intervention: typical ant ipsychot ic drug
Comparison: atypical ant ipsychot ic drug
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Atypical antipsychotic
drug
Typical antipsychotic
drug
Duration of delirium
Follow-up: days
This outcome was not
reported in any trial.
Delirium resolution
DRS, DRS-R981
Follow-up: 7 days
Study population RR 1.1
(0.79 to 1.52)
349
(5 studies)
⊕⊕©©
Low-quality: we are
moderately conf ident in
the ef fect est imate; the
true ef fect is likely to
be close to the est imate
of ef fect, but there is a
possibility that it is sub-
stant ially dif f erent.2,3
305 per 1000 335 per 1000
(241 to 463)
Moderate
313 per 1000 344 per 1000
(247 to 476)
Delirium severity
DRS, DRS-R981
Follow-up: 7 days
The mean DRS-R-98
score was 29.7 (SD 4.
6)
8.0 (SD 6.9) at the end
of study.10
The standardised delir-
ium severity score was
0.17 points lower in the
intervent ion group (0.
37 lower to 0.02 higher)
542
(7 studies)
⊕⊕©©
Low-quality: we are
moderately conf ident in
the ef fect est imate; the
true ef fect is likely to
be close to the est imate
of ef fect, but there is a
SMD -0.17 (-0.37 to 0.
02)
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possibility that it is sub-
stant ially dif f erent.4,5
Mortality
Follow-up: 7 days
Study population RR 1.71
(0.82 to 3.53)
342
(4 studies)
⊕⊕©©
Low-quality: we are
moderately conf ident in
the ef fect est imate; the
true ef fect is likely to
be close to the est imate
of ef fect, but there is a
possibility that it is sub-
stant ially dif f erent.6
62 per 1000 106 per 1000
(51 to 219)
Moderate
18 per 1000 31 per 1000
(15 to 64)
Hospital length of stay
Follow-up: days
This outcome was not
reported in any trial.
Adverse Effects - EPS
Follow-up: 7 days
Study population RR 12.16
(0.55 to 269.52)
198
(2 studies)
⊕©©©
Very low-quality: we
have very lit t le conf i-
dence in the ef fect es-
t imate; the true ef fect
is likely to be substan-
t ially dif f erent f rom the
est imate of ef fect.7,8,9
0 per 1000 0 per 1000
(0 to 0)
Moderate
0 per 1000 0 per 1000
(0 to 0)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; DRS: Delirium Rating Scale; DRS-R98 = Delirium Rating Scale Revised 98; EPS: Extrapyramidal Symptoms; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 DRS = Delirium Rating Scale; DRS-R98 = Delirium Rating Scale Revised 98
2 All included trials had risk of bias.24
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3 Delirium resolut ion was measured with dif f erent tools at variable t ime points using dif ferent thresholds.
4 Only 1 of 7 trials was considered low risk of bias across all domains. Six of the seven trials had blinded delirium assessment.
5 Delirium severity was measured with dif f erent tools at variable t ime points.
6 Low number of events.
7 All t rials at risk of bias.
8 Variable tools used to assess.
9 Few events and wide conf idence intervals.
10 Assumed risk taken f rom Maneeton 2013.
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D I S C U S S I O N
Summary of main results
We identified nine randomised trials evaluating antipsychotics for
treatment of delirium in hospitalised, non-ICU patients. Four of
the trials compared antipsychotics to nonantipsychotic drugs or
placebo and seven compared typical to atypical antipsychotics.
We found no evidence for determining the effect of antipsychotic
drugs (as a class or by type) on duration of delirium. The cur-
rent evidence does not support the use of an antipsychotic drug
to reduce delirium severity, shorten time to resolution, or reduce
mortality. We found no evidence to determine the effect of an-
tipsychotics on length of hospital stay or health-related quality of
life. Low-quality evidence showed adverse drug events were infre-
quently assessed but available data indicated extrapyramidal side
effects were notmore commonwith antipsychotic drugs compared
to nonantipsychotic drugs or placebo and typical antipsychotics
(e.g. haloperidol) were comparable to atypical antipsychotics (e.g.
risperidone).
Overall completeness and applicability of
evidence
The original version of this Cochrane Review included three trials
(Lonergan 2007). We had anticipated finding a large number of
new trials investigating antipsychotics for a number of reasons,
including the known association between delirium and adverse
patient outcomes, that delirium is deemed publicly important and
is an indicator of quality of care in the elderly, and the fact that the
2010 NICE guidelines recommended further research. Despite
the ten-year time lapse since the original version of this review,
the body of evidence for treatment of delirium for hospitalised
non-ICU patients with antipsychotic drugs remains limited and
fraught with issues. Although we identified nine trials for inclu-
sion, none of the trials reported on delirium duration, length of
hospital stay, hospital discharge destination, health-related quality
of life, andmany of the adverse events we perceivedwere important
to patients, families and clinicians. Most of the studies were single
centre studies with insufficient sample size, heterogeneous study
populations, and at risk of bias. Only one trial was an adequately
powered trial that included a placebo group (Agar 2016) with low
risk of bias across all domains. It is also important to note there
were differences in how some of the outcomes were measured in
the trials. For example, there were sufficient studies to pool for
the outcomes, delirium severity and resolution of symptoms, but
different tools were used and the time points assessed were not
consistent. Our planned subgroup analyses to determine if there
were differences in effect/safety in the older or dementia partici-
pant populations could not be addressed because of lack of data.
We had anticipated finding more evidence in these populations as
delirium is common in these subgroups.
Quality of the evidence
We scored the risk of bias for each trial and used GRADEpro
software to inform the generation of evidence quality statements.
Of the nine randomised controlled trials included in this review,
only one trial scored low risk of bias across all domains. Although
this review included only randomised controlled trials, the qual-
ity of evidence was downgraded for risk of bias, inconsistency,
or imprecision. There were some notable design issues of these
trials that should be factored into future trials. Guidelines sug-
gest antipsychotics only be considered once non-drug strategies
are considered ineffective or insufficient for the distressed patient.
Only half of the identified trials reported that non-drug strategies
were used during the study period and details of the interventions
applied were not provided. Also, the use of rescue therapies for
agitation, such as benzodiazepines, was not consistently reported.
Physical restraint use was not reported in any trial. Use of chemical
and physical restraint as rescue therapy presents an opportunity
to introduce bias and thus should be standardised and reported
in future trials. There was heterogeneity for some outcomes and
their measurement methods. For the outcomes, severity and res-
olution of delirium, variable tools were used, different definitions
or thresholds were applied, and the outcomes were assessed at dif-
ferent time points. In future trials, one must also consider the fact
that delirium severity rating scales tend to focus more on hyperac-
tive delirium, which is less common, rather than hypoactive delir-
ium.
Potential biases in the review process
This review followed theCochrane procedures and there were only
a small number of amendments to the review process (outlined in
Differences between protocol and review).
Agreement and disagreements with other
studies or reviews
The original version of this Cochrane Review did not answer the
specific question of the effect of antipsychotics compared to no
antipsychotics on delirium outcomes in hospitalised non-ICU pa-
tients. We believe it is critical to first understand if antipsychotics
as a class are effective and safe for management of delirium be-
fore comparing typical and atypical antipsychotics. We have ex-
panded on the original review to answer this specific question be-
fore comparing typical and atypical antipsychotics. On the advice
of Cochrane, we also narrowed the population by excluding the
clinically unique critically ill patient population.
Our principal finding was consistent with a recent comprehensive
review by Neufeld and colleagues (Neufeld 2016). Neufeld and
colleagues did not find the available evidence supported antipsy-
chotic use for prevention or treatment of delirium in any hos-
pitalised patient population. This review included studies of any
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design (prospective or historical cohort, case-control, and other
observational designs) and they included both ICU and non-ICU
participant populations. The generated outcomes were based on
nearly all trials enrolling only critically ill participants. Kirshi and
colleagues (Kishi 2016) similarly conducted a systematic review
to examine antipsychotics for treatment of delirium. The review
also included both ICU and non-ICU participant populations in
15 studies. Four of the studies included were unpublished or in
abstract form only; these were excluded from our review as well
as the Neufeld review. The primary outcomes measure for Kir-
shi’s review was response rate at the study end point, examining
many different severity and global scales. They found antipsy-
chotics were superior to placebo or nonantipsychotic drugs in this
analysis of ICU and non-ICU studies in terms of response rate
(RR 0.22, 95% CI 0.15 to 0.34, P < 0.00001, I² = 0%, three
studies). When they performed a subgroup analysis using only
ICU studies they found the pooled result was marginally superior
to placebo or nonantipsychotic drugs (RR 0.25, 95% CI 0.06 to
1.02, p = 0.05, N = 1); using only non-ICU studies the result was
the same as the pooled ICU and non-ICU studies with antipsy-
chotics significantly superior to no antipsychotic (RR 0.22, 95%
CI 0.15 to 0.34, P < 0.00001, I² = 0%, two studies). Similarly for
the analysis of delirium severity, antipsychotics were significantly
superior to no antipsychotic (SMD -1.27, 95% CI -2.44 to -0.11,
P = 0.03, I2 = 93%, two studies). For these analyses, we included
two additional trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• Survey data indicates pharmacological interventions, such
as antipsychotics, are often used to manage delirium symptoms
in clinical practice. The 2010 NICE guidelines (NICE 2010)
recommended clinicians should investigate and manage
underlying or reversible causes of delirium. For patients that are
distressed, verbal and nonverbal techniques should be used to
manage symptoms; if these strategies are ineffective or
insufficient, short-term (< 1 week) antipsychotic drug might be
considered at the lowest effective dose.
• After updating this review, we caution clinicians to the fact
that there is still insufficient evidence overall on this subject. We
found no evidence to determine whether antipsychotics reduce
delirium duration in hospitalised non-ICU patients (our primary
objective). We found low-quality evidence that antipsychotics do
not reduce delirium severity compared to nonantipsychotic
drugs or placebo and low-quality evidence indicating there is no
difference between typical and atypical antipsychotics. There is
low-quality evidence that antipsychotics do not alter mortality or
adverse event rates in delirious hospitalised patients.
Implications for research
• The 2010 NICE guidelines (NICE 2010) recommended
that a large RCT should be conducted to compare typical
antipsychotics and atypical antipsychotics with placebo in
hospitalised patients with delirium. The NICE guidelines also
recommended the study outcomes of such a trial should include
recovery from delirium (defined as complete response), the
duration and severity of delirium (measured with a validated
tool), as well as clinically important adverse events. Such a trial
has been completed for palliative care participants (Agar 2016)
but not for other important hospitalised non-ICU populations.
• Our search identified a number of delirium studies
published in the last decade suggesting a growing interest in this
subject. However, the majority of recent studies have focused on
critically ill participants, still leaving us with insufficient poor
quality data for hospitalised, non-critically ill participants (e.g.
general medicine, surgery). Given the limited available evidence
for this review, the 2010 NICE guideline recommendations
calling for new research is still justified in 2018. Well designed
controlled trials are urgently needed to address this population
who are frequently managed with antipsychotics despite limited
evidence. In particular, we need adequately powered trials that
include a placebo group and factor in nonpharmacological
delirium treatment strategies that have already been shown to be
helpful in this population to clarify if an antipsychotic alters
delirium outcomes. These trials should clearly standardise and
describe the use of rescue interventions to manage agitation (e.g.
benzodiazepines and physical restraints), as such interventions
are known to be associated with delirium and can introduce bias.
• Our search revealed limited data on outcomes that we
deemed important for patients, their families, and the clinical
team. Future studies need to examine the effect of therapy on
duration of delirium or time to complete resolution, length of
hospital stay, and long-term outcomes, such as cognitive
impairment. In addition, to improve comparison of results
among trials there is a need for standardisation of research
methods and outcomes reported, specifically duration of therapy
and methods of evaluating response to delirium treatment. The
Del-COrS (Development of core outcome sets for effectiveness
trial of interventions to prevent and/or treat delirium) group
(Rose 2017) is leading the development of international
consensus on outcomes for trials of interventions to prevent and/
or treat delirium for critically ill, acutely hospitalised participants,
palliative care, and older adults. The recommendations from this
group will be essential for future well designed delirium trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agar 2016
Methods Double-blind, randomised trial comparing risperidone, haloperidol, and placebo on
targeting symptoms of delirium
Participants Location: Study took place in 11 inpatient hospice or palliative care services in Australia.
Inclusion: Participants included adult patients receiving hospice or palliative care with
advanced, progressive disease that was no longer curable who required inpatient care by a
specialist palliative care team. Participants were required to speak English and be able to
swallow liquids. Participants needed to meet the following 3 criteria: delirium diagnosis
via 1) DSM-IV-TR criteria, 2) Memorial Delirium Assessment Scale (MDAS) score of
7 or more, and 3) presence of the target symptoms of delirium associated with distress,
defined as a delirium symptoms score of 1 or more (sum of the scores from items 2
(inappropriate behaviour), 3 (inappropriate communication), and 4 (illusions and hallu-
cinations) on the Nursing Delirium Screening Scale (NuDESC) (severity range, 0 to 6)).
Exclusion: delirium due to substance withdrawal, history of neuroleptic malignant syn-
drome or previous adverse reaction to an antipsychotic drug, regular use of antipsychotic
drugs within 48 hours of the study, extrapyramidal disorders, prolonged QT interval,
clinician-predicted survival of 7 days or fewer, cerebrovascular accident or seizure in the
prior 30 days, and pregnancy or breastfeeding. Subjects included: 247 adult participants
(N = 82 risperidone, mean age 74.5 ± 10.6 years, 57/82 (69%) male, N = 81 haloperidol,
mean age 76.5 ± 8.2 years, 48/81 (59%) male, N = 84 placebo, mean age 73.8 ± 10.7
years, 57/84 (68%) male)
Interventions Each study drug arm: 1) Participants ≤ 65 years received a 0.5 mg loading dose of
study drug administered with the first dose of 0.5 mg, then 0.5 mg maintenance doses
every 12 hours. Doses could be titrated by 0.25 mg on day 1 and by 0.5 mg thereafter
to a maximum dose of 4 mg/d. 2) For participants > 65 years, the loading, initial,
and maximum doses of the study drug were halved. The placebo solution was titrated
similarly using matching volumes of solution for each dose level. Doses were increased
if the sum of NuDESC scores for items 2, 3, and 4 was 1 or more at the most recent
assessment. Participants were observed daily, with NuDESC scores measured every 8
hours by trained nurses. Dose reduction of the prior dose could occur for adverse effects,
resolution of delirium (MDAS score of < 7 for 48 hours), or resolution of symptoms (all
NuDESC item scores < 1 for 48 hours). Treatment duration was 72 hours, with the last
assessment done 12 hours after the sixth dose
Study drugwas discontinued if adverse effects became unacceptable, the treating clinician
deemed the treatment ineffective, or at onset of dysphagia. Maintenance of blinded study
medication was optional for an additional 48 hours if a partial response occurred or
to taper the dose with resolution of symptoms. All participants received individualised
treatment plans, including treatment of reversible precipitants, where clinically indicated,
and nonpharmacologic measures, as appropriate. Rescue drug: Subcutaneous midazolam
2.5 mg every 2 hours PRN was available when participants in any group scored 2 on
the NuDESC item for inappropriate behaviour or illusions and hallucinations, and were
deemed to require immediate intervention for safety or distress. Intravenous benztropine
mesylate (1 to 2 mg) could be administered for serious extrapyramidal adverse effects
35Antipsychotics for treatment of delirium in hospitalised non-ICU patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Agar 2016 (Continued)
Outcomes Clinical (day 3): 1) Average of last 2 delirium symptom scores on day 3, using the baseline
score (average of the eligibility delirium symptom score and the score before the first dose
of the study drug) as a covariate, 2) Daily MDAS score, 3) Lowest delirium symptoms
score, 4) Daily use of midazolam (rescue drug), 5) Sedation, assessed by the Richmond
Agitation-Sedation Scale, 6) Survival (measured at day 3 and also median survival (days))
. Adverse effects: 1) Extrapyramidal symptoms, assessed by the Extrapyramidal Symptom
Rating Scale, 2) National Cancer Institute Common Terminology Criteria for Adverse
Events
Notes Study was funded by the Australian Government’s Department of Health under the
National Palliative Care Strategy. Individual site funding was supplemented by grant
NHMRC 480476 from the National Health and Medical Research Council, Australia.
The trial was registered (ACTRN12607000562471). Baseline covariates collected in-
cluded: prior cognitive impairment (all cause), Informant Questionnaire on Cognitive
Decline in the Elderly score, comorbidity burden (Cumulative Illness Rating Scale score)
, vision or hearing impairment, daily oral morphine and diazepam equivalents, and the
Australia-modified Karnofsky Performance Status score
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Site randomisation schedules generated us-
ing random number tables at an indepen-
dent and blinded central registry. Partici-
pants were randomised in blocks of 6 by
site in a 1:1:1 ratio
Allocation concealment (selection bias) Low risk Sealed opaque envelopes were used. Site
clinical trial pharmacists not otherwise in-
volved in patient care opened treatment
schedules to prepare study drug
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded study - both participants
and investigators were masked to treatment
groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat basis. Missing scores im-
puted using multiple imputation, drawing
50 resamples
Selective reporting (reporting bias) Low risk Outcomes in methods matched those re-
ported in results. Trial protocol was pre-
registered
Other bias Low risk All participants were permitted pain med-
ication, rescue benzodiazepine, and given
similar nonpharmacological interventions.
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Power calculations presented
Breitbart 1996
Methods Double-blind, randomised trial comparing haloperidol, chlorpromazine, and lorazepam
in the treatment of delirium
Participants Location: Study took place in a single general medicine unit of one hospital in the United
States. Inclusion: Medically hospitalised adults whomet the case definition for AIDS and
who were undergoing treatment for AIDS-related medical problems at a single hospital
were approached for participation. They recruited and consented participants prior to
the episode of delirium. Participants were followed prospectively and not randomised
to study drug unless they became delirious. Exclusion: AIDS-related dementia where
participants could not give informed consent, patients expected to die within 24 hours,
known hypersensitivity to study drugs, history of neuroleptic malignant syndrome, con-
current need for treatment with neuroleptic drugs, seizure disorder, current systemic
chemotherapy for Kaposi’s sarcoma, withdrawal syndrome, current/past diagnosis for
schizophrenia, schizoaffective disorder, or bipolar disorder
Subjects included 30 adult participants (N = 11 haloperidol, N = 13 chlorpromazine, N
= 6 lorazepam, mean age of entire study population 39.2 ± 8.8 years, 23/30 (77%) male)
hospitalised for AIDS-related medical problems and diagnosed with delirium (DSM-III
criteria and Delirium Rating Scale (DRS) total score ≥13)
Interventions The study did not include a placebo group. The authors believed withholding medica-
tion from agitated participants could pose a risk to patients and staff, hence they did
not use a placebo group. They viewed lorazepam as a placebo. Study drug: Participants
were randomised to one of three groups by pharmacy personnel. Groups were: haloperi-
dol, chlorpromazine, and lorazepam. Subjects were started on the lowest dose of their
respective study drug, administered either orally or intramuscularly and according to an
a priori established increasing titration schedule consisting of 9 levels of dosing (table
1 in manuscript). Haloperidol was started with 0.25 mg oral/0.125 mg intramuscular,
chlorpromazine at 10 mg oral/5 mg intramuscular, and lorazepam at 0.5 mg oral/0.20
mg intramuscular. Each subject was evaluated hourly using theDRS. If, after each hourly
evaluation, the participant’s DRS score remained ≥13, the next level dose of study drug
was administered. After stabilisation (i.e. participant calm, asleep, not hallucinating, and
DRS ≤ 12), a maintenance dose equal to one-half of the first 24-hour dose requirement
was begun, given in a twice-daily regimen from day 2 of the study until a maximum of six
days of treatment. Midway through the study, the participants in one group developed
treatment-limiting adverse side effects as per the manuscript. All participants were in
the lorazepam group. From that point forward, no further participants were randomised
to the lorazepam group. Rescue drugs: No rescue drugs permitted (additional details
provided by author)
Outcomes Outcomes (at end of study drug, day 6):
1. Mean drug doses administered in first 24 hours of treatment, 2. Average maintenance
doses of study drug, 3. DRS score, change from baseline to day 2, and day 2 to day
6, 4. Mini-Mental State score, change from baseline to day 2, and day 2 to day 6, 5.
Karnofsky Performance Status, 6. Medical Status Profile. Adverse effects: 1) Extrapyra-
midal symptoms, assessed by the Extrapyramidal Symptom Rating Scale, 2. Side Effects
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Breitbart 1996 (Continued)
and Symptom Checklist
Notes Study supported by the National Institute of Mental Health grant MH-45664
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation table
(additional details provided by author)
Allocation concealment (selection bias) Low risk Pharmacist not involved in the study pa-
tient care indicated which study drug was
to be used based on the random number
table
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded study.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Lorazepam arm discontinued early due to
adverse events, but data used in analysis
Selective reporting (reporting bias) Unclear risk Outcomes in methods matched those re-
ported in results. But protocol not pub-
lished to confirm all outcomes were re-
ported as planned
Other bias Unclear risk No rescue drugs permitted (additional de-
tails provided by author). Also, midway
through the study, the participants in one
group developed treatment-limiting ad-
verse side effects as per the manuscript. All
participants were in the lorazepam group.
From that point forward, no further partic-
ipants were randomised to the lorazepam
group
Note: Sample size/power calculationnot re-
ported in the manuscript
Grover 2011
Methods Single-blind, randomised trial comparing haloperidol, risperidone, and olanzapine in
the treatment of delirium
Participants Location: Conducted in single hospital in India. Inclusion: Consecutive participants
with delirium referred to the consultation-liaison psychiatry team were eligible for the
study. To be included in the study, participants had to have a confirmed diagnosis
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of delirium and > 18 years of age. Exclusion: Participants with delirium secondary
to alcohol or benzodiazepine withdrawal, those with dementia, those unresponsive to
verbal or physical stimulus, those suffering terminal illness, and those with a comorbid
psychotic/mood disorder, profound hearing or visual loss, aphasia, Parkinson’s disease,
history of neuroleptic malignant syndrome, prolonged QTc interval, past history of
hypersensitivity to any of the study drugs. Participants included 64 adult (> 18 years)
medical and surgical patients (N = 20 haloperidol, mean age 44.09 ± 16.84 years, 12/
20 (60%) male, N = 21 risperidone, mean age 45.39 ± 19.18 years, 12/21 (57%) male,
N = 23 olanzapine, mean age 46.5 ± 14.51 years, 21/23 (91%) males) diagnosed with
delirium (CAM and DRS-R-98)
Interventions There were three study groups: 1) Haloperidol: flexible dose ranging from 0.25 to 10
mg/day; 2) Risperidone: flexible dose ranging from 0.25 to 4 mg/day; and 3) Olanza-
pine: flexible dose ranging from 1.25 to 20 mg/day. Study drug was administered for
6 days and for all subjects, family members told to follow behavioural management (i.
e. providing optimal level of environmental stimulation, reducing sensory impairments,
making environment more familiar, providing environmental cues that facilitate orien-
tation, and providing reassurance and information concerning delirium so as to reduce
fear or demoralisation). Delirium screening occurred daily. For all participants, the etio-
logical causes identified for delirium were treated with appropriate measures. Any med-
ication that can cause delirium and/or was not essential for the care of the participant
was discontinued. Rescue drugs: For the haloperidol and olanzapine groups, whenever
rescue medication was required (e.g. severe agitation), the same drug was used in the
injectable form. For the risperidone group, injectable lorazepam or haloperidol was used
as rescue medication as risperidone not available in injectable form. The dose of rescue
medication was titrated after daily clinical assessment; however, if the participant was
agitated, titration was done more frequently
Outcomes Outcomes (daily for 6 days by blinded investigator): 1. DRS-R-98 score, 2. Mini Mental
Status Examination score. Adverse effects: 1. Simpson Angus Scale for side effects, 2.
Abnormal Involuntary Movement Scale, 3. Udvalg for Kliniske Undersogelser score side
effect rating scale
Notes Study funded by Institute Research Fund. Protocol not published
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised but no details pro-
vided. It is likely that it was done
Allocation concealment (selection bias) Low risk Randomisation and dose adjustments were
carried out by one study investigator, how-
ever, assessments were blinded
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single-blinded study. However, all assess-
mentswere carried out by a single investiga-
tor (different from the one who performed
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Grover 2011 (Continued)
the randomisation and dose adjustments)
who was blinded to study drug allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 74 participants consented, 64 com-
pleted the study. Six participants could not
be assessed at least once during the study
(due to worsened clinical status) and four
left hospital against medical advice
Selective reporting (reporting bias) Unclear risk Outcomes in methods matched those re-
ported in results. Trial protocol not pub-
lished so unable to confirm all outcomes
were reported as planned
Other bias Unclear risk For both groups, etiological causes of delir-
ium were addressed and nonessential med-
ications or medications associated with
delirium were discontinued. One group
(i.e. risperidone) received lorazepam or
haloperidol as injectable risperidone was
not available. However, haloperidol and
olanzapine groups received the same drug
they were assigned to for rescue. Referral
bias: participants who were referred to the
consultation-liaison psychiatry team were
eligible for the study. It is unknown if all
participants with suspected delirium are
routinely referred to psychiatry in this hos-
pital
Note: Sample size/power calculationnot re-
ported.
Grover 2016
Methods Single-blind, randomised controlled trial of quetiapine and haloperidol for the treatment
of delirium
Participants Location: Study conducted in single hospital in India. Inclusion: Consecutive patients
with delirium referred to the consultation-liaison psychiatry team were eligible for the
study. Only patients who fulfilled a diagnosis of delirium based on DSM-IV and > 18
years could be included in the study. Exclusion: delirium due to alcohol or benzodi-
azepine withdrawal, poisoning, overdoses, dementia, those unresponsive to verbal or
physical stimulus, history of aphasia, profound hearing or visual loss, those with QTc
prolongation, past history of hypersensitivity to the study drugs, history of neuroleptic
malignant syndrome, Parkinson’s disease, psychotic or mood disorders, and terminal ill-
ness. Participants included 63 adult (> 18 years) medical and surgical patients (N = 31
quetiapine, mean age 48.51 ± 19.75 years, 21/31 (68%) male, N = 32 haloperidol, mean
age 44.4 ± 16.76 years, 28/32 (88%) male) diagnosed with delirium (DSM-IV criteria)
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Interventions No placebo group. The study compared: 1) Haloperidol: flexible dose ranging from 0.
25 to 10 mg/day and 2) Quetiapine: flexible dose ranging from 12.5 to 75 mg/day.
Study drug was adjusted daily as per the clinical judgement of treating physician who
was blinded to assignment. Study drug was administered for 6 days. For all subjects,
caregivers advised to provide optimal level of environmental stimulation, avoid sensory
impairments of the participant, and make the environment familiar to the participant by
ensuring proper environmental cues that could facilitate orientation. Delirium screening
occurred daily. Rescue drugs: Benzodiazepines were not permitted. Use of other drugs
to manage severe agitation not reported
Outcomes Outcomes (at end of study drug, day 6): 1. DRS-R-98 score, 2. Mini Mental Status
Examination score, 3. Average dose of study drug, 4. Delirium response rates (DRS-R-
98 < 10), 5. Delirium resolution rates (DRS-R-98 score of 0). Adverse effects: None
included as an outcome or reported
Notes Protocol not published in advance.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done based on a
computer-generated randomisation table,
which was done prior to study start
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Single-blinded study, however the inves-
tigator responsible for randomisation and
drug titration was different from the one
who conducted the outcome assessments
(blinded clinical assessment)
Incomplete outcome data (attrition bias)
All outcomes
High risk Seven participants not included in the anal-
ysis. Two participants in each group were
not available for assessment after the first
1 to 2 study days because they left against
medical advice. One participant in the que-
tiapine group received injectable haloperi-
dol for symptommanagement on study day
2, and was excluded. One participant from
each group could not be started on the as-
signed medication due to medical deterio-
ration
Selective reporting (reporting bias) Unclear risk Outcomes in methods matched those re-
ported in results. Trial protocol not pub-
lished so unable to confirm all outcomes
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were reported as planned
Other bias Unclear risk Mansucript source reported as ’invited
manuscript.’ Referral bias (same as Grover
2011): participants who were referred to
the consultation-liaison psychiatry team
were eligible for the study. It is unknown
if all participants with suspected delirium
are routinely referred to psychiatry in this
hospital
Note: Sample size/power calculationnot re-
ported.
Han 2004
Methods Double-blind, randomised trial of risperidone versus haloperidol in the treatment of
delirium
Participants Location: Study took place in a single hospital in Korea. Inclusion: All patients present-
ing with altered mental status who were referred to the consulting psychiatry division
were evaluated. Delirium was confirmed with the Confusion Assessment Method and
Delirium Rating Scale. Exclusion: any type of dementia or other psychiatric diagno-
sis, patients already administered an antipsychotic prior to screening for disturbing be-
havioural problems. Subjects included 24 adult patients (N = 12 haloperidol, mean age
66.5 ± 15.9 years, 7/12 (58%) male, N = 12 risperidone, mean age 65.6 ± 8.3 years, 6/12
(50%) male) from four medical, two intensive care, and two oncology wards, diagnosed
with delirium (CAM, DRS)
Interventions No placebo group included in this study. Study groups: haloperidol: flexible dose, initial
dose of 0.75 mg twice a day versus risperidone: flexible dose, initial dose of 0.5 mg twice
a day. Study drug dose was increased depending on the status of delirium during the 7
days of treatment. Delirium was assessed daily. Rescue drugs: None reported
Outcomes Outcomes (One psychiatrist, blind to the status of treatment, measured the symptom
changes at the same time every day for 7 days): 1. Time to response (Memorial Delirium
Assessment Scale (MDAS) score < 13), 2. Response rate (MDAS < 13), 3. Mean drug
dose at end of study (day 7). Adverse effects: None included as an outcome. In the results
section, it was stated ’None of the 24 subjects who finished the study showed clinically
significant side effects’. Method of assessment or which specific side effects examined
were not reported
Notes Primary investigator supported by the Brain Korea 21 Project of the Ministry of Educa-
tion and Human Resources Development, Republic of Korea
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk A consulting psychiatrist (not a member
of the investigative team) randomly as-
signed participants without any knowledge
of their care. Method of sequence genera-
tion not provided
Allocation concealment (selection bias) Unclear risk Stated as a double-blind study. However,
authors stated it was not possible to obtain
identical looking tablets but the ’patients
and caretakers did not know the name or
effects of their drug’. Likely blinded
Blinding (performance bias and detection
bias)
All outcomes
Low risk Stated as a double-blind study. However,
authors stated it was not possible to obtain
identical looking tablets but the ’patients
and caretakers did not know the name or
effects of their drug’. Unlikely to have been
double-blinded in design. However, a psy-
chiatrist, blind to participant status and
treatment, measured symptom change at
the same time for a total of 7 days
Incomplete outcome data (attrition bias)
All outcomes
High risk Intially, N = 28 and final sample of N = 24.
Two participants in the haloperidol group
dropped out: one because of medical de-
terioration on the second study day, and
one because of severe sedation on the third
study day. Two participants in the risperi-
done group dropped out: one because of
spousal refusal to participate on the sec-
ond study day, and one because of a tra-
cheotomy operation on the fourth study
day. Attrition not reported in the analysis
Selective reporting (reporting bias) Unclear risk Trial protocol not found.
Other bias Low risk Sample size calculation not reported.
Hu 2004
Methods Randomised trial comparing olanzapine, haloperidol, and placebo in the treatment of
delirium
Participants Location: Study took place in a single hospital in China. Inclusion: age > 65 years, either
male or female, delirium based on DSM-IV, DRS ≥ 12, total clinical global impression
scale-severity of illness (CGI-SI) > 4.
Exclusion: Patients with a severe mental disease, those who had taken any antipsychotic
drug, patients with angle-closure glaucoma, paralytic ileus, or material abuse. Subjects
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included 175 hospitalised patients (N = 74 olanzapine, mean age 74 ± 8 years, 45/74
(60.8%) male, N = 72 haloperidol, mean age 74 ± 7 years, 48/72 (66.7%) male, N =
29 placebo, mean age 73 ± 7 years, 18/29 (62.1%) male) with a history of dementia
admitted to any of the hospital’s wards and diagnosed with delirium (DSM-IV, DRS
score ≥12 and Clinical Global Impression-Severity of Illness (CGI-SI) score ≥ 4)
Interventions Study drug: Olanzapine was started at a daily dose of 1.25 to 2.5 mg PO, and increased
to a maximum daily dose of 20mg.Haloperidol was administered in a daily dose range of
2.5 to 10 mg, intramuscularly (starting dose not provided). If CGI-SI score was reduced
by≥ 1, the dose was maintained and study drug was administered for 7 days. All subjects
received ’somatic’ treatment aimed at the etiological factors of delirium. Delirium was
evaluated daily using theDRS and theCGI.Rescue drugs:Noother centrally actingdrugs
were permitted, except in the instance of the development of extrapyramidal symptoms,
where a maximum dose of 6 mg of banzhexol was administered
Outcomes Outcomes (day 7): 1. DRS score, change from baseline to study completion, 2. CGI-SI
(Severity) score, change from baseline to study completion, 3. CGI (Global Impression)
score, change from baseline to study completion, 4. Dose and time to effect in cases
where delirium was successfully treated. Adverse effects: None included as an outcome
Notes This study was referred to as (Hua 2006) in certain reviews. The original study, cited
here, was subsequently translated into English and published under the title ’Olanzapine
and haloperidol for senile delirium: a randomised controlled observation’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of method of randomisa-
tion beyond stating participants were ran-
domised in a 5:5:2 ratio to olanzapine,
haloperidol, and placebo groups, respec-
tively
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding (performance bias and detection
bias)
All outcomes
High risk Haloperidol could be given subcutaneously
and olanzapine orally. No description of
how treatments were concealed. No men-
tion of blinding process. Not likely done
Incomplete outcome data (attrition bias)
All outcomes
High risk No mention of how attrition was factored
into statistical analysis (not described as in-
tention-to-treat analysis)
Selective reporting (reporting bias) Low risk Trial protocol identified under the first
name.
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Other bias Unclear risk Sample size not reported. Unclear method-
ology regarding dosing protocol
Lin 2008
Methods Randomised trial of haloperidol versus olanzapine in the treatment of delirium
Participants Location: Study conducted in a single hospital in Taiwan. Inclusion: All participants
were recruited from the hospice and palliative care center, had advanced cancer, met
the DSM-IV criteria for delirium. Exclusion: past history of psychiatric disorder, coma,
could not swallow oral medication, treated with neuroleptic drug within 4 weeks of the
study. Subjects included 30 adult palliative and hospice care patients (N = 16 olanzapine,
mean age 61.13 ± 16.5 years, 9/16 (56%) male, N = 14 haloperidol, mean age 68 ± 12.
14 years, 4/14 (29%) male) diagnosed with delirium (DSM-IV criteria)
Interventions Study drug: Haloperidol: starting dose of 5 mg PO daily, permitted daily maximum dose
15 mg versus Olanzapine: starting dose of 5 mg PO daily, permitted daily maximum
dose 15 mg. Study drug administered for 7 days. Delirium assessed via the Delirium
Rating Scale (Chinese version) (DRS-c) at 24 and 48 hours, and oneweek into treatment.
Rescue drugs: If adjunctive therapy required for acute symptoms, midazolam IM was
used
Outcomes Outcomes (day 7): 1. DRS-c at baseline, 24 and 48 hours, and 7 days into treatment, 2.
Clinical Global Impression-Severity (CGI-S) at baseline, 24 and 48 hours, and 7 days
into treatment. All assessments were conducted by one assessor (research nurse) that was
blinded to study assignment. Adverse effects:
1) side effects were observed and recorded on the chart by the clinical team and the
assessor of the study without formal instruments
Notes Trial details/protocol not published in advance.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as a prospective randomised con-
trolled clinical trial. Likely randomised.
Methods of randomisation not stated
Allocation concealment (selection bias) Unclear risk Insufficient details to assess. Stated that if
participant needed an antipsychotic, they
were ’separated randomly to an olanzapine
group or a haldol group’
Blinding (performance bias and detection
bias)
All outcomes
Low risk A single individual, a nurse and coun-
selling psychologist, performed all assess-
ments. The assessor was blinded to subject
randomisation
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Incomplete outcome data (attrition bias)
All outcomes
High risk Total number of participants enrolled and/
or lost to follow-up not reported
Selective reporting (reporting bias) Unclear risk Outcomes in methods matched those re-
ported in results. Trial protocol not pub-
lished so unable to confirm all outcomes
were reported as planned
Other bias Unclear risk Referral bias: A psychiatric specialist deter-
mined whether it was necessary for the par-
ticipant to receive antipsychotic drug treat-
ment based on clinical grounds. If an an-
tipsychotic was deemed needed (criteria for
use not provided), the participants were
consented and randomised
Note: Sample size calculation not reported.
Maneeton 2013
Methods Randomised trial of quetiapine versus haloperidol in the treatment of delirium
Participants Location: Study took place in a single tertiary care hospital in Thailand. Inclusion: All
inpatients presumed to have delirium and needing consultation-liaison services from the
psychiatric department were evaluated for inclusion, Delirium confirmed with DSM-
IV. Exclusion: substance-induced delirium, known allergy or intolerance to study drugs,
pregnancy or breast feeding, already receiving an antipsychotic drug, renal or hepatic
failure. Subjects included 52 medically ill adult (aged 18 to 75 years) patients (N = 24
quetiapine, mean age 56.6 ± 12 years, 15/24 (62.5%) male, N = 28 haloperidol, mean
age 57 ± 11.9 years, 20/28 (71%) male) diagnosed with delirium (DSM-IV-TR and
CAM criteria)
Interventions Study drugs:Quetiapine: flexible dose ranging from25 to 100mg/day versus haloperidol:
flexible dose ranging from 0.5 to 2 mg/day. Study drug given at bedtime for 7 days, with
additional doses as needed. Drug dose was adjusted based on clinical safety, sleepiness,
and calmness, as measured by the Delirium Rating Scale (DRS-R-98). Subject given
one dose and another every 2 to 3 hours as needed for agitation, with a daily maximum
of four doses. Delirium was assessed daily via the DRS-R-98. All participants were
assessed for possible causes of delirium that could be corrected using the mnemonic
’IWATCHDEATH’. Environmental manipulations emphasised, such as noise control,
light intensity, reassurance, and stimulusmodification. Rescue drugs:Other psychotropic
drugs, including benzodiazepines, were prohibited
Outcomes Outcomes (day 7): 1.DRS-R-98 severity score, 2.DRS-R-98 noncognitive and cognitive
subscale scores, 3. Delirium response rate (50% reduction of baseline DRS-R-98 score)
, 4. Delirium remission rate (DRS-R-98 severity score of 12 or less without relapse), 5.
Total time of sleep, 6. Clinical Global Impression-Improvement (CGI-I), 7. Modified
Simpson-Angus Scale (MSAS). Adverse effects: 1) Participants were assessed for possible
adverse events either observed by the investigators, relatives, clinical staff, or self-report.
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Maneeton 2013 (Continued)
Formal tool not used
Notes Study funded by the Faculty ofMedicine, ChiangMai University, ChiangMai, Thailand
(grant number 077/52)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation sys-
tem. Subjects randomly assigned in a 1:1
manner to one of the two study groups.
Randomisation codes were kept in sealed
envelopes and opened after the end of the
screening process
Allocation concealment (selection bias) Low risk Double-blinded study. Study medication,
either 25mgquetiapine or 0.5mghaloperi-
dol, was fully filled and concealed in iden-
tical capsules
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded study. Participants, physi-
cians, staff nurses, investigators, and raters
were blinded to treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk Authors reported 32.7% study with-
drawal. Stated 13/24 quetiapine- and 22/
28 haloperidol-treated participants com-
pleted the study. They used intention-to-
treat analysis if a participant received at least
one dose of the study drug
Selective reporting (reporting bias) Low risk Outcomes in methods matched those re-
ported in protocol.
Other bias Unclear risk Trial was registered with clinicaltrials.gov
(CNT00954603). Referral bias: All inpa-
tients presumed to have delirium and need-
ing consultation-liaison services from the
psychiatric department were evaluated for
inclusion
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Tahir 2010
Methods Randomised trial comparing quetiapine versus placebo in the treatment of delirium
Participants Location: Study took place in a single hospital in the United Kingdom. Inclusion: DSM-
IV criteria for delirium. Exclusion: major pre-existing cognitive deficits (major not de-
fined), alcohol withdrawal, pre-existing psychosis, substance dependence, inability to
comply with the constraints of the trial, on medication that interacted with quetiapine.
Subjects included 42 patients (N = 21 quetiapine, mean age 84.1 ± 9.45 years, 6/21
(28.6%) male, N = 21 placebo, mean age 84.3 ± 7.16 years, 6/21 (28.6%) male) from
medical, surgical, and orthopedic units diagnosed with delirium (DRS-R-98 total score
≥ 15, confirmed by DSM-IV criteria)
Interventions Study drugs: Participants received quetiapine or placebo, according to a flexible dosing
regimen begun at 25 mg daily, with a dose titration of 25 mg/day to a maximum of
175 mg/day, in divided doses. The dose was increased only if DRS-R-98 and clinical
condition showed no improvement and the drug was well tolerated, up to a maximum of
10 days. In addition to the clinical response and tolerability, information from nursing
and medical staff was also considered prior to dose changes. If symptoms improved, dose
was reduced in a reverse pattern from initial titration. Delirium assessment via DRS-R-
98 on study days 1, 2, 3, 4, 7, and 10, with an additional follow-up on day 30. Rescue
drugs: Not specified in the methods. However results reported use of lorazepam
Outcomes Outcomes (up to day 10): 1. DRS-R-98 score, 2. Mini-Mental Status Examination,
3. Brief Psychiatric Rating Scale, 4. Clinical Global Improvement. Adverse effects: 1.
Abnormal Involuntary Movement Scale
Notes Investigator-initiated study sponsored by AstraZeneca UK. Funding provided for re-
cruitment of a research assistant and trial medication. AstraZeneca UK also provided the
randomisation codes. This study was stopped early
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
codes.
Allocation concealment (selection bias) Low risk Computer-generated randomisation codes
kept in sealed envelopes in the pharmacy.
Set of individual treatment codes kept for
emergency out-of-hours use only
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Non-linear, mixed effects models used to
estimate differences in recovery trajecto-
ries. Reasoning for the use of this statisti-
cal method described in a subsequent paper
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Tahir 2010 (Continued)
published by the authors
Selective reporting (reporting bias) Low risk Registered trial.
Other bias Unclear risk Sample size calculation reported. The trial
was stopped early at the request of the
manufacturer due to the FDA’s concern
on the use of antipsychotic medication in
the elderly. The study is, therefore, under-
powered. Lorazepam was administered to
4 participants in the the quetiapine group
versus none in the placebo group. The
quetiapine had faster resolution; unclear if
this might have influenced the resolution
of symptoms. Investigator-initiated study
sponsored by AstraZeneca UK. Funding
provided for recruitment of a research assis-
tant and trial medication. AstraZeneca UK
also provided the randomisation codes
AIDS=AcquiredImmunodef iciencySyndrome
CAM = Confusion Assessment Method
CGI = Clinical Global Impression
CGI-SI = Clinical Global Impression - Severity Scale index
DRS = Delirium Rating Scale
DRS-c = Delirium Rating Scale (Chinese version)
DRS-R-98 = Delirium Rating Scale Revised 98
DSM = Diagnostic and Statistical Manual of Mental Disorders
IM = Intramuscular injection
MDAS = Memorial Delirium Assessment Scale
NuDESC = Nursing Delirium Screening Scale
PO = per os or by mouth
PRN = pro re nata or as needed
QTc = QT interval corrected for rate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al Qadheeb 2016 Study population was intensive care unit patients.
Atalan 2013 Study population was intensive care unit patients.
Bakri 2015 Study population was intensive care unit patients.
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(Continued)
Devlin 2010 Study population was intensive care unit patients.
Girard 2010 Study population was intensive care unit patients.
Hakim 2012 Study population was intensive care unit patients.
Jung 2009 Compared two second generation antipsychotics (risperidone and aripiprazole) with no nonantipsychotic or
placebo comparator
Jung 2010 Compared two second generation antipsychotics (risperidone and quetiapine) with no nonantipsychotic or
placebo comparator
Kim 2010 Compared two second generation antipsychotics (risperidone and olanzapine) with no nonantipsychotic or
placebo comparator
Lee 2005 Compared two second generation antipsychotics (amisulpride and quetiapine) with no nonantipsychotic or
placebo comparator
Page 2013 Study population was intensive care unit patients.
Reade 2009 Study population was intensive care unit patients.
Reade 2016 Study population was intensive care unit patients.
Sakong 2010 Compared two second generation antipsychotics (risperidone and aripiprazole) with no nonantipsychotic or
placebo comparator
Skrobik 2014 Study population was intensive care unit patients.
Characteristics of studies awaiting assessment [ordered by study ID]
Djokic 2008
Methods Randomised controlled trial to determine the efficiency of risperidone in the treatment of delirium superimposed on
dementia
Participants Study took place in a single hospital in Serbia. N = 120 subjects with mean age of 73.57 years, predominantly female
(60.3%), with Alzheimer’s disease (60%), dementia in Parkinson’s disease (6%), vascular dementia (23%)
Interventions Participants were randomly assigned to control group (haloperidol 1 to 4mg/24h) or experimental group (risperidone
0.5 to 2 mg/24h) up to 28 days. Both groups were treated according to the underlying cause of delirium. All
participants were assessed with The Memorial Delirium Assessment Scale (MDAS), MMSE, Brief agitation Rating
Scale (BARS) and GCI scales daily
Outcomes 1. Change in MDAS scores (day 14, day 28), 2. Change in BARS scores (day 10, day 28), 3. CGI-I scores (day 28),
4. Mortality
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Djokic 2008 (Continued)
Notes Published in conference abstract form only. Unable to obtain further details from author to establish firm eligibility
Jung Jin 2009
Methods Randomised, open prospective study to compare intramuscular olanzapine and intramuscular haloperidol for patients
with delirium
Participants N = 62 hospitalised patients admitted to single hospital in South Korea. Patients were diagnosed as having delirium
by two independent psychiatrists using DSM-IV-TR
Interventions Intramuscular injection olanzapine and intramuscular injection of haloperidol. Details of dose and frequency not
provided in the abstract
Outcomes 1. DeliriumRating Scale-revised-98 (DRS-R-98), 2. Clinical Global Impression-Severity (CGI-S), 3. Simpson-Angus
Rating Scale, 4. Barnes Akathisia Rating Scale, 5. Abnormal Involuntary Movement Scale
Notes Numeric results not reported. Published in conference abstract form only. Unable to obtain further details from
author to establish firm eligibility
Lee 2013
Methods Randomised trial comparing the efficacy and safety of aripiprazole and haloperidol in the treatment of delirium
Participants N = 26 patients with delirium (Korean Version of Delirium Rating Scale-revised-98 (KDRS- 98))
20 participants were analysed at the end.
Interventions Aripiprazole or haloperidol. No information provided on the dose, titration, formulation, or duration of therapy
Outcomes 1. The Korean Version of Delirium Rating Scale-revised-98 (KDRS- 98) and Korean Version of Drug Induced
Extrapyramidal Symptom Scale (DIEPSS-K) were assessed, 2. Blood samples were collected to analyse serum sodium
ion concentration, plasma cortisol and prolactin level and pulse oximetry were used for measuring oxygen saturation.
Time points of assessment not reported in the abstract
Notes Numeric results not reported. Published in conference abstract form only. Unable to obtain further details from
author to establish firm eligibility
Nakamura 1997
Methods Open label randomised trial of haloperidol and mianserin in the treatment of delirium
Participants Individuals undergoing neuropsychiatric referrals.
Interventions Haloperidol: flexible dose of 2 to 6 mg/day per os at bed time. Mianserin: flexible dose of 10 to 60 mg/day per os at
bed time
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Nakamura 1997 (Continued)
Outcomes 1. Change in delirium severity, as measured by the DRS at baseline and study day 7, 2. Delirium resolution, defined
as ≥ 50% reduction in baseline DRS score
Notes Published in full but unable to obtain further details from author to establish study population, exact number of
individuals treated in each group, and delirium inclusion criteria
BARS=BriefAgitationRatingScale
CGI-S = Clinical Global Impression - Severity Scale
CGI-I = Clinical Global Impression - Improvement Scale
DIEPSS-K = Korean Version of Drug Induced Extrapyramidal Symptom Scale
DRS = Delirium Rating Scale
DSM = Diagnostic and Statistical Manual of Mental Disorders
GCI =Clinical Global Impression
KDRS-98 = Korean Version of Delirium Rating Scale-revised-98
MDAS = Memorial Delirium Assessment Scale
MMSE = Mini Mental State Examination
Characteristics of ongoing studies [ordered by study ID]
NCT02345902
Trial name or title Randomised double-blind clinical trial to compare haloperidol and nonpharmacologic treatment versus non-
pharmacologic treatment and placebo, in elderly hospitalised patients with hypoactive delirium
Methods Double-blind RCT of haloperidol versus placebo added to nonpharmacologic treatment for delirium
Participants Study taking place in a single hospital in Mexico. Participants included hospitalised patients aged 70 years
with delirium diagnosis according to the CAM or Delirium Observation Screening Scale (DOSS) and not
taking any antipsychotics
Interventions Haloperidol: 1.25 mg administered orally x 9 days. Placebo: matched placebo tablet, 1.25 mg administered
orally x 9 days. Both groups will undergo nonpharmacologic delirium interventions: A. Reorientation (i.e.
calendar, clocks, familiar objects), B. Glasses and hearing devices, where needed, C. Avoidance of physical
restraints, D. Limitation of excessive personnel shifts or hospital room, E. A tranquil and comfortable envi-
ronment, especially at night, to avoid interruptions (i.e. dim light, low levels of noise), F. Adequate schedules
for medication administration and to take vital signs or medical procedures, G. Sleep hygiene (light in the
room and movement during the day), H. Avoidance of dehydration, and I. Avoidance of medications use
which are associated with delirium (e.g. psychoactive medications)
Outcomes 1. Change in delirium severity (via Delirium Observation Screening Scale), 2. Use of rescue haloperidol, 3.
Durationof delirium, 4. Perceived stress (viaDeliriumExperienceQuestionnaire), 5. Incidence of PTSD(Mini
International Neuropsychiatry Interview), 6. Cognitive impairment (via Montreal Cognitive Assessment), 7.
Cerebral blood flow (via transcranial Doppler), 8. Adverse events (e.g. extrapyramidal symptoms, arrhythmias,
QTc prolongation)
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NCT02345902 (Continued)
Starting date January 2016
Contact information Dr. Maria Carmen Flores (mcflormir@gmail.com) and Dr. Sara Aguilar-Navarro (sgan30@hotmail.com)
Notes Study sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Estimated study com-
pletion: October 2018. Trial registration: https://clinicaltrials.gov/ct2/show/NCT02345902
CAM=Conf usionAssessmentMethod
DOSS = Delirium Observation Screening Scale
PTSD = Post Traumatic Stress Disorder
QTc = QT interval corrected for rate
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D A T A A N D A N A L Y S E S
Comparison 1. Severity of delirium
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Antipsychotic versus no
antipsychotic
4 494 Std. Mean Difference (IV, Random, 95% CI) -1.08 [-2.55, 0.39]
2 Sensitivity analysis (placebo-
controlled studies only)
3 464 Std. Mean Difference (IV, Random, 95% CI) -0.89 [-2.64, 0.86]
3 Sensitivity analysis (trials at low
risk of bias)
2 289 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.22, 0.27]
4 Typical versus atypical
antipsychotic
7 542 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.37, 0.02]
Comparison 2. Resolution
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Antipsychotic versus no
antipsychotic
3 247 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.30, 2.98]
2 Sensitivity analysis (including
placebo studies)
2 217 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.58, 3.54]
3 Resolution (atypical versus
typical antipsychotic)
5 349 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.79, 1.52]
Comparison 3. Mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (antipsychotic versus
no antipsychotic)
3 319 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.73, 2.27]
2 Sensitivity analysis (including
only placebo studies)
2 289 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.75, 2.66]
3 Mortality (atypical versus typical
antipsychotic)
4 342 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.82, 3.53]
54Antipsychotics for treatment of delirium in hospitalised non-ICU patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 4. Adverse Event
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Antipsychotic versus no
antipsychotic (EPS)
3 247 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.04, 65.57]
2 Typical versus atypical
antipsychotic (EPS)
2 198 Risk Ratio (M-H, Random, 95% CI) 12.16 [0.55, 269.52]
WH A T ’ S N E W
Last assessed as up-to-date: 20 July 2017.
Date Event Description
20 July 2017 New citation required and conclusions have changed New studies added and content extensively revised. Conclu-
sions changed. Changes to author team and new lead author
20 July 2017 New search has been performed Top-up searches were performed for this review inMay 2011,
July 2013, October 2015, November 2016 and July 20 2017.
New studies were identified for inclusion in the review
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 2, 2007
Date Event Description
23 October 2008 Amended Converted to new review format.
2 February 2007 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
LB and LR reviewed the search results.
SM, MMP, JSL, and CB extracted data for included studies.
LB, BH and DAF completed the analysis and generated the ’Summary of Findings’ table and GRADE Evidence.
LB generated the first draft of the review.
NS acted as an independent arbiter for study exclusion, and verified ’risk of bias’ assessments.
All authors interpreted the analysis and contributed to the write-up of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Pharmacy, Mount Sinai Hospital, Toronto, Canada.
External sources
• Canadian Frality Network (Previously known as Technology Evaluation in the Elderly Network [TVN] (www.tvn-nce.ca)),
Canada.
Funded by the Government of Canada through the Networks of Centres of Excellence (NCE), Technology Evaluation in the Elderly
facilitates evidence-based research, knowledge sharing and clinical practices that improve healthcare outcomes for frail elderly
Canadians, their families and caregivers.
• NIHR, UK.
This update was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the
Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• The original protocol has been modified to exclude critically ill patients as this population overlaps with the Cochrane
Anaesthesia, Critical and Emergency Care Group’s Protocol ACE311.
• Antipsychotics are the most commonly prescribed class of drug for the treatment of delirium in hospitalised patients. We felt it
necessary to refine the original protocol’s research question ’to compare the efficacy and incidence of adverse effects of haloperidol
with risperidone, olanzapine, and quetiapine in the treatment of delirium’ to instead explore the effects of antipsychotics versus
alternative (i.e. nonantipsychotic drugs) or placebo on outcomes of hospitalised patients with delirium. We made the original primary
question a secondary question.
• We included Health-related quality of life as an outcome and expanded upon the adverse events that we sought from the trials.
• The ’Summary of findings’ table was generated in accordance with current Cochrane Collaboration Guidance utilising GRADE
assessments.
• Authorship for this update has been changed to include new members and remove those no longer involved in the review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antipsychotic Agents [adverse effects; ∗therapeutic use]; Benzodiazepines [adverse effects; therapeutic use]; Delirium [∗drug therapy];
Haloperidol [adverse effects; therapeutic use]; Randomized Controlled Trials as Topic; Risperidone [adverse effects; therapeutic use]
MeSH check words
Adult; Female; Humans; Male
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